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Acinetobacter baumannii is an important microorganism involved in hospital-acquired 
infections with a remarkable ability to develop resistance to multiple antibiotics (multidrug-
resistance, MDR) which makes it a highly troublesome pathogen in many hospitals around 
the world. Third-generation cephalosporins (such as ceftazidime) and carbapenems (such as 
imipenem and meropenem) represent important treatment options for infections caused by 
this microorganism. Nevertheless, the number of strains resistant to these antibiotics has 
been increasing during the last decade. 
 
The ability to capture, mobilise and regulate the expression of resistance-genes of this 
microorganism is a cornerstone factor in the development of the MDR, where the Mobilome, 
defined as “all the mobile genetic elements in a cell”, is responsible for its genetic plasticity. 
 
The aim of this work was to analyse the role of insertion sequences (ISs), transposon-like 
structures, resistance-plasmids and ISCR1-like elements in the resistance to carbapenems and 
ceftazidime in A. baumannii. Fifteen carbapanem-resistant strains of Acinetobacter 
baumannii isolated from Chile and two ceftazidime-resistant strains from the United Arab 
Emirates were studied. Different ceftazidime- and carbapenem-resistance genes were 
analysed and their genetic environments were characterised. 
 
The Mobilome in the carbapenem-resistant strains was composed of insertion sequences 
(ISs), specifically by ISAba1 associated with blaOXA-51-like, ISAba3 associated to blaOXA-58, 




the case of the ceftazidime-resistant strain, the presence of an ISCR1 element was harbouring 
the blaPER-7, which was detected in a megaplasmid. 
 
The Mobilome, in the strains analysed, was composed of a wide variety of genetic elements, 
such as plasmids, insertion sequences, ISCR-like elements, which reflects the ability of A. 
baumannii to use different genetic platforms to capture and use resistance genes, making the 
Mobilome an important contributor in the resistance and the dissemination of resistance 
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Chapter 1 Introduction 
 
1.1.  A short history of antibiotics 
 
1.1.1.  The pre-penicillin era. 
Antibiotics are defined, in modern terms, as “any synthetic or naturally occurring low 
molecular weight molecule that inhibits bacterial growth” (Gillings, 2013). The history of 
antibiotics starts back in 1400s with the use of bismuth and mercury in the treatment of 
syphilis caused by Treponema pallidum (Shlaes, 2010). These compounds are harmful to 
people but, in proper doses, they are more toxic to the disease-causing microorganism. The 
“modern era” of antibiotics started in the beginning of the 20th century, when Paul Ehrlich 
introduced an arsenical-compound, arsphenamine, for the treatment of diseases caused by 
microbes. This new antibiotic compound, also known as Salvarasan, was successful for the 
treatment of microbial infections and thanks to its high effectiveness, was called the 
“Ehrlich’s magic bullet” (Bosch and Rosich, 2008; Shlaes, 2010). Due to his discovery, 
Ehrlich was awarded with the Nobel Prize of Medicine in 1908. However, the usage of this 
drug was restricted as it is also toxic for humans as it is an arsenic-based compound. It was 
necessary to develop new innocuous compounds able to attack only the infectious 
microorganisms. Later, in the 1930’s, sulphonamides were identified as new options for 
bacterial infections. The first drug of this new group, Prontosil, was synthetized by Bayer 
chemists (Domagk, 1957). This drug was a prodrug, which after be metabolised produces its 
active form, sulfanilamide (reviewed by Shlaes, 2010). As in the case of “Ehrlich’s magic 
bullets”, Gerhard Domagk, who was responsible of the characterisation of the antimicrobial 
capacity of Prontosil, won the Nobel Prize of Medicine in 1939. Mainly due to their low 
manufacturing costs, sulfonamides were produced in large quantities and used widely to treat 




health, a study carried out in 1938 in a hospital from Chicago USA; it showed that the 
mortality among patients with pneumonia, treated with Dagenan (sulphonamide) ranged 
between 6 to 17.6% while in the untreated patients group, the mortality rates oscillated 
between 23 to 50% (reviewed by Shlaes, 2010). However, these drugs were effective against 
a limited number of bacterial pathogens and had no effect on several infection-producing 
microorganisms (reviewed by Guilfoile, 2007).  
 
1.1.2.  The antibiotic revolution 
In 1928, Sir Alexander Fleming and his group made one of the most important contributions 
in the history of modern medicine. He and his colleagues studied the antibiotic properties of 
Penicillium notatum, a mould able to produce a molecule which inhibits the bacterial growth. 
This compound had a stronger activity than sulfonamides and affected a broader spectrum of 
microorganism (Fleming, 1929). It was not until 1940 that a chemistry group led by Ernest 
Chain and Howard Florey purified the antibiotic compound, called penicillin and by 1945 
they were able to produce large quantities of this new drug (Ligon, 2004). The first use of 
penicillin in England was in 1941. A patient with a serious infection caused by 
Staphylococcus aureus, previously treated with sulfonamides, was then treated with a limited 
amount of penicillin, and the infection was controlled (reviewed by Guilfoile, 2007). 
Following this success, penicillin usage increased widely and the improvement of the 
chemical processes to find and synthesize antibiotics enabled the discovery of a number of 
new agents. The 1945-1960 period is known as the “golden era” of antibiotics, where most 
of the classes of antibiotics, currently in clinical use, were initially characterised (Wright, 
2007).  
The following decade, between 1970-1980, was a period where a considerable number of 




antibiotics, in order to overcome bacterial resistance and increased their effectiveness. The 
manufacture of these semi-synthetic antibiotics led to this period being known as the “golden 
age of antibiotic medicinal chemistry” (Wright, 2007). Nonetheless, after this period, the 
number of new antibiotics approved for clinical use decreased alarmingly, mainly due to the 
rapid appearance of resistant bacteria. Only a few new antibiotics were approved in the late 
1990’s and early 2000’s, such as linezolid, tigecycline and daptomycin, resulting in 
reduction of therapeutic options to treat microbial infections. In this sense, Sir Alexander 
Fleming, during his Nobel lecture in 1945, expressed a major concern about the misuse of 
antibiotics, saying that “there may be a danger in underdosage. It is not difficult to make 
microbes resistant to penicillin in the laboratory by exposing them to concentrations not 
sufficient to kill them, and the same thing has occasionally happened in the body” 
(Alexander Fleming, Penicillin, Nobel Lecture, December 11, 1945). This message was the 

















1.2.  Types of antibiotics 
The antibiotics can be characterised according to their chemical structures and mechanism of 
action.  
 
1.2.1.  Structural classes. 
 
1.2.1.1.  β-lactams 
 
More than half of the antibiotics available today and some currently in development are β-
lactams; this is due to their high effectiveness and safety (Nicolau, 2008). The principal 
structural feature of these drugs is the presence of the β-lactam ring, also known as 
“chemical warhead” (Guilfoile, 2007).  Figure 1.1 shows the structure of penicillins, the first 





    
Figure 1. General structure of penicillins. The β-lactam ring is highlighted in the black box 
(adapted from -Guilfoile, 2007). R – side chain. 
 
There are four main subgroups of β-lactams including penicillins, cephalosporins, 





This subgroup comprises the original drug, called Penicillin G or benzylpenicillin and its 
derivatives including ampicillin, amoxicillin and methicillin (Miller, 2002). Penicillin G is 
still currently widely used. The penicillin-derivate are antimicrobials generated by chemical 
modifications of the side chain (R- as represented in Figure 1) on the basic nucleus of 
penicillin (Wright and Wilkowske, 1987). The aim of the modification of the side chain is to 
increase their antibacterial activity, resist enzymatic hydrolysis (penicinillases) and improve 
their pharmacokinetic properties (Sköld, 2011).   
 
Cephalosporins 
The cephalosporins subgroup are closely related to penicillin, but they were extracted from a 
different microorganism, Cephalosporium acremonium. The first member of this subgroup, 
cephalosporin C, was discovered in 1948 by Giuseppe Brotzu when he studied the ability of 





Figure 2. Chemical structure of cephalosporins. R1 – side chain 1; R2 – side chain 2.  
 
The cephalosporins differ from penicillin by possessing a six-membered heterocyclic ring, 
containing a sulphur atom (dihydrothiazine ring) attached to the β-lactam structural ring 
(Figure 2).  The variations in the chain sides (R1 and R2 in Figure 2) increase their 




host (Kalman and Barriere, 1990). Currently there are five generations of cephalosporins 
based to some extent on the year of development but also on their spectrum of activity 
(Kollef, 2009).  
 
First generation cephalosporins are effective against Gram-positive and Gram-negative 
bacteria but poorly effective against anaerobic microbes while second-generation 
cephalosporins have a broader-antibacterial activity including, specifically in the case of 
cefoxitin, activity against anaerobic pathogens (reviewed by Kalman and Barriere, 1990). 
Third-generation cephalosporins are very effective against Enterobacteriaceae and also, in 
the case of ceftazidime and cefoperazone, they are very active against P. aeruginosa. 
Whereas fourth-generation cephalosporins (cefepime and cefpirome) are more resistant to β-
lactamases and their action spectrum includes methicillin-resistant Staphylococcus aureus 
(MRSA), largely because of their rapid penetration (Bijie et al., 2005). Ceftopribole and 
ceftaroline, which comprise the fifth generation of cephalosporins, are resistant to β-
lactamases produced by S. aureus and have a high affinity for the PBP 2a of MRSA, 
representing a useful alternative for treating infections caused by this multidrug-resistant 
pathogen (Duplessis and Crum-Cianflone, 2011; Kisgen and Whitney, 2008). 
 
Monobactams 
This subgroup of β-lactams comprises a unique member, aztreonam (Duma, 1988). This 
compound was produced by a soil bacterium, Chromobacterium violaceum (Johnson and 
Cunha, 1995). The β-lactam ring is not attached to an extra ring (monocyclic β-lactam) 
unlike cephalosporins and penicillins (Figure 3). This is the simplest β-lactam with 









Figure 3. Chemical structure of aztreonam (Sköld, 2011). 
 
Aztreonam is only effective against aerobic Gram-negative bacilli so it must be 
administrated in conjunction with other antibiotics in many cases (Guay and Koskoletos, 
1985). Monobactams do have an important characteristic; they do not induce allergic 
reactions in penicillin-allergic patients (Johnson and Cunha, 1995), representing a helpful 
alternative to treat patients with this condition. 
 
Carbapenems 
This last subgroup of β-lactams are derived from thienamycin, produced by a soil 
microorganism, named Streptomyces cattleya (Kahan et al., 1979). As with other members 
of the β-lactam group, these drugs are formed around a β-lactam ring, as shown in Figure 4. 
They differ from cephalosporins in that the β-lactam ring is fused to a five-member 
thiazolidine ring. The differences with penicillins are the substitution of the sulphur atom, in 
the five member ring, for a carbon atom and the presence of an unsaturated bond in the 








Figure 4. Comparison between the chemical structures of β-lactams (Knapp and English, 
2001). 
 
Structurally, the carbapenems differ from each other by their side chain (Figure 5). The first 
carbapenem, imipenem, was approved in 1987. However, this drug was degraded by the 
enzyme dehydropeptidase (DHP-1), present in the renal tubules (reviewed by Zhanel et al., 
2007). To avoid this degradation, imipenem is supplied with cilastatin, a compound that 
inhibits DHP-1 (Norrby, 1995). Meropenem, the second member of the subgroup, was 
approved in 1996. This antimicrobial differs from imipenem in that it was not inhibited by 
DHP-1 (Norrby, 1995) and could also be given to children. These antimicrobial agents 
possess a broad spectrum of activity, affecting mainly Gram-negative, but also some, Gram-
positive pathogens and also are effective in the treatment of nosocomial (hospital-acquired) 
infections (Zhanel et al., 2007). Meropenem differs from imipenem in possessing a 
pyrrolinidyl group at the position 2 which may be the reason of its higher activity against 
Gram-negative pathogens in comparison with imipenem (Zhanel et al., 2005). 
 
Ertapenem, approved in 2001, is an antimicrobial drug used to treat complicated infections 
not involving nosocomial pathogens, such as Enterococcus spp. and non-fermentative Gram-
negative pathogens (Livermore et al., 2003). Doripenem was approved in 2012 by the US 
Food and Drug Administraion (FDA), for the treatment of adults with complicated intra-




et al., 2013). The broad spectrum of activity is associated to the stability against hydrolytic 
degradation (Zhanel et al., 2007).  
 
 
Figure 5. Chemical structure of carbapenems. The side chains are highlighted in the black 
boxes (adapted from Zhanel et al., 2007). The arrows show the carbon 6 of the chemical 
structure of carbapenems. 
 
This stability is due to the presence of a trans-α-1-hydroxyethyl substituent at the 6 position, 
which is exclusive when compared with cephalosporins and penicillins, where there is a cis 
configuration (Moellering et al., 1989). Due to the characteristics described above, these 
antimicrobial drugs represent an important alternative to the treatment of serious infections 
and to the elimination of resistant-bacteria. 
 
1.2.1.2.  Tetracyclines 
Tetracyclines are antimicrobial drugs produced by many species members of the 




minocycline are the main members of this group (Griffin et al., 2010). The name refers to 
their chemical structure that is composed by a four-ring core carrying different functional 
members; for instance, the oxytetracycline, produced by S. rimosus, has a hydroxyl group in 





Figure 6. Chemical structure of oxytetracycline (Sköld, 2011). 
 
Tetracyclines are very effective against many different pathogens, hence are classified as 
broad-spectrum drugs that are also effective against mycoplasma, intracellular chlamydiae, 





1.2.1.3.  Aminoglycosides 
The first aminoglycoside, streptomycin, was isolated by Selman Waksman in 1943 from 
Streptomyces griseus (Raju, 1999), representing the third clinically useful natural antibiotic 
discovered after penicillin. In the beginning, streptomycin was widely used against 
Mycobacterium tuberculosis, depicting the first antibiotic used to treat tuberculosis (Sköld, 
2011). The chemical structure of aminoglycosides, illustrated in Figure 7, shows that the 
molecule is composed of two or more amino sugars (aminoglyco) fused to an amino-cyclitol 






Figure 7. Chemical structure of streptomycin (adapted from Skold, 2011). 
 
Later in 1949, neomycin was isolated from Streptomyces fradiae followed by kanamycin, 
which was isolated, in 1957, from Streptomyces kanamyceticus (Begg and Barclay, 1995). 
Afterwards, another important member of this group, gentamicin, was obtained from 
Micromonospora purpurea (Weinstein et al., 1963). Netilmicin, tobramycin and amikacin 
were introduced after 1976 (Begg and Barclay, 1995). Tobramycin, netilmicin, gentamicin 
and amikacin are currently being used in clinical practice while streptomycin is not generally 
used because of its side effects, such as nephrotoxicity and ototoxicity  (Begg and Barclay, 
1995; Sköld, 2011). They are several factors favouring aminoglycoside use, for example 
synergism with β-lactams, clinical effectiveness and rapid concentration-dependent 




1.2.1.4.  Macrolides 
The first member of this group used clinically, erythromycin (Figure 8), was discovered in 
1952 and was produced by Streptomyces erythreus. It consisted of a large lactone ring 
(macro) with two attached sugar substituents (Douthwaite and Champney, 2001). The 
members of this group possess a complex chemical structure formed by a macro-lactone ring 







Figure 8. Chemical structure of erythromycin (Sköld, 2011). 
 
Erythromycin is effective against Gram-positive cocci, such as Streptococcus pneumoniae, 
Streptococcus pyogenes and S. aureus, and also possesses activity against Mycoplasma 
pneumoniae, Legionella pneumophila and Chlamydia pneumoniae (Shah, 1998). Due to 
some limitations of erythromycin, such as poor oral bioavailability, a short half-life in the 
host, side effects, and drug-drug interactions, new macrolides were designed in order to 
improve pharmacokinetic properties (reviewed by Zhanel et al., 2001). These new 
macrolides members, such as clarithromycin and azithromycin, have better pharmacokinetic 
properties and higher antimicrobial activity (Carbon, 1995). However, the number of 
resistant-bacteria has increased rapidly, decreasing the use of macrolides. In order to 




was developed, named ketolides, that possess a keto group in their 14-membered lactone ring 
and, clinically, ketolides differ from macrolides in that they do not induce macrolide 
resistance in S. pneumoniae (Bryskier, 1998). 
 
1.2.1.5.  Quinolones 
In 1962, the first quinolone antibiotic, nalidixic acid, was introduced into medical practice. 
Nalidixic acid is a synthetic drug that is active mainly against Gram-negative microbes 
(Oliphant and Green, 2002). After the introduction of nalidixic acid, several antibiotics 
derived from it were designed, such as gatifloxacin, levofloxacin and ciprofloxacin, which 
are useful for treating urinary infections caused by Gram-negative enterobacteria (Sköld, 
2011). The chemical structure of quinolones comprises two rings, with a nitrogen in position 






Figure 9. Chemical structure of quinolones (Alós, 2009). 
 
Quinolones are divided in generations according to their spectrum of activity (Naber and 
Adam, 1998). The first generation quinolones, comprising nalidixic acid and pipemidic acid, 
have activity mainly against Enterobacteriaceae. Since the second generation, a fluoride 
atom was included in the structure of quinolones, in the position 6, enabling them to be 
called fluoroquinolones (Blondeau, 2004). In general terms, fluoroquinolones (such as 




generation quinolones, representing important agents to treat infections caused by Gram-
negative, Gram-positive and atypical pathogens (Blondeau, 2004). 
 
1.2.1.6.  Sulfonamides 
These drugs represent the first group of truly selective antibacterial agents approved for 
medical use. Sulfonamides were introduced in 1935. The selectivity of sulfonamides is due 
to the fact they inhibit a bacterial enzyme, dihydropteroate synthetase, which involved in 
important metabolic pathway in bacteria but it does not exist in mammalian cells 
(McCullough and Maren, 1973). The name is because the presence of a sulphur atom in their 





Figure 10. Chemical structure of sulfonamide (Sköld, 2011) 
Because they are easy and cheap to synthesize, sulfonamides were extensively used decades 
ago but their use is very limited nowadays. This decline has mainly been due to the 
appearance of more effective drugs, the emergence of bacterial resistance and their 
considerable side effects, such as allergic reactions including Steven-Johnson syndrome 






1.2.1.7.  Trimethoprim 
Trimethoprim was first used for the treatment of infections in humans in 1962 (Huovinen et 
al., 1995). This drug, administrated alone, was used as prophylaxis for urinary tract 
infections in Finland, in 1972; when it was introduced to treat patients with acute urinary 
infections in 1979 (Huovinen, 2001). This drug is related to sulfonamides in the sense that it 
interferes the same metabolic pathway in bacteria (Sköld, 2011). According to its chemical 
structure (Figure 11), trimethoprim corresponds to a structural analog of the folic acid pterin 
moiety, thereby inhibiting the enzyme dihydrofolate reductase in bacteria. The selective 
action of trimethoprim, affecting only to the bacterial cells, allows its clinical use at low 






Figure 11. Chemical structure of trimethoprim (Sköld, 2011). 
 
Since trimethoprim and sulfonamides, specifically sulfamethoxazole, attack successive steps 
in the same metabolic pathway, they have been used in combination, being known as 
cotrimoxazole (Sköld, 2011). This drug combination was originally a first-line option for the 
treatment of urinary tract infections, sinusitis and acute bronchitis (reviewed by Strevel et 
al., 2006), but the toxicity of the sulphonamide component means that the combination is 
now rarely used in the manority of countries. However, it is sometimes used as a prophylaxis 




caused by Pneumocystis jiroveci (Manyando et al., 2013) and nocardiosis (Eshraghi et al., 
2014). 
 
1.2.1.8.  Others 
Chloramphenicol was introduced in the 1950s. This drug was the first broad-spectrum 
bacteriostatic antibiotic affecting both Gram-negative and Gram-positive pathogens 
(Wareham and Wilson, 2002). This drug is able to cross through the blood-brain barrier 
ensuring that it is an important drug for treating meningitis (van Niekerk et al., 1980; Sköld, 
2011). Nevertheless, it is used principally for external purposes, as skin unguent and eye 
drops; and it is not use for the systemic treatment of bacterial infections because its side 
effects, blood dyscrasias, which can cause irreversible and fatal aplastic anaemia (Sköld, 
2011). 
Rifampicin, a member of the rifamycin family with antibacterial activity, was introduced in 
1967. This compound does not share any chemical similarity with other families of 
antibiotics (Furesz, 1970). Rifampicin has a broad spectrum activity, although Gram-
negative rods, such as E. coli, are less susceptible due to the poor ability of the large 
rifampicin molecule to penetrate the lipopolysaccharide (LPS) barrier (Sköld, 2011). Its use 
is almost exclusively to treat infections caused by M. tuberculosis (Guilfoile, 2007); 
although because its low toxicity, its use has been increasing as a combination antimicrobial 
therapy for the treatment of various infections, including infections caused by S. aureus, S. 
pneumoniae, Legionella spp., Rhodococcus spp. and infections caused by fungus (reviewed 
by Forrest and Tamura, 2010). Interestingly, in a murine model of A. baumannii pneumonia 
caused by susceptible, intermediate or resistant strains, rifampicin, as a monotherapy, was 
more effective in reducing microorganisms in the infection site than imipenem, sulbactam, 




monotherapy, should be managed under strict control because it induces the rapid 
appearance of resistant strains both in vitro and in vivo (Garnacho-Montero and Amaya-
Villar, 2010).  Additionally, rifampicin could be used in combination with other antibiotics 
in order to treat infections caused by MDR-A. baumannii; for example, rifampicin in 
combination with polymyxins, such as colistin, has been used to treat infections caused by 
nosocomial MDR strains (Bassetti et al., 2008). Similarly, rifampicin in combination with 
imipenem or sulbactam showed high efficacy against MDR A. baumannii in experimental 
models of meningitis and pneumonia (Pachón-Ibáñez et al., 2010). 
Another important group of antibiotics comprise the polymyxins. Currently there are two 
polymyxins available for clinical usage, colistin (polymixin E) and polymixin B (Landman et 
al., 2008). Colistin was discovered in 1949 and is produced by Bacillus polymyxa subspecies 
colistinus Koyama (Falagas and Kasiakou, 2005). Polymyxins have been used worldwide in 
topical otic treatments and as ear drops for decades (Falagas and Kasiakou, 2005). These 
drugs have bactericidal activity against a wide number of Gram-negative pathogens, such as 
Escherichia coli, P. aeruginosa, Acinetobacter spp., etc. (Landman et al., 2008). The usage 
of polymyxins was stopped during the next decade following its introduction, owing to their 
toxicity, specifically nephrotoxicity (Kwa et al., 2008). However, the use of polymyxins, 
specifically colistin, has risen during the last decade mainly because the appearance of 
multidrug resistant MDR-pathogens (Landman et al., 2008). According to a work published 
by Jimenez et al., a case of meningitis caused by a MDR-A. baumannii strain was treated by 
administration of colistin every 6 h, which stopped the infection (Jiménez-Mejías et al., 
2002). Additionally, in order to treat MDR pathogens, colistin can be co-administrated with 
other antibiotics. For example, in the treatment of infections caused by MDR-pathogens in 
patients with cystic fibrosis, the administration of colistin with an antipseudomonal agents, 
such as ceftazidime or ciprofloxacin, is more effective than the treatment with colistin alone 




of colistin and rifampicin has a synergistic bactericidal activity against MDR-pathogens. 
Additionally, it has been demonstrated that the combination of colistin and ceftazidime is 
active against MDR P. aeruginosa in vitro (Gunderson et al., 2003) as the combination of 
colistin, rifampicin and amikacin has been used for the treatment of infections caused by 
MDR P. aeruginosa in an immunocompromised patient (Tascini et al., 2000). In the case of 
polymyxin B, it has a lower activity against P. aeruginosa, Salmonella spp. and Shigella spp. 
than colistin (Falagas and Kasiakou, 2005). 
Glycopeptides represents another important group of antimicrobial agents. These antibiotics 
are active against Gram-positive bacteria but they do not have activity against Gram negative 
pathogens (Colabella and Chagan, 2008). Specifically, relative to other antimicrobials, 
glycopeptides are larger molecules, which prevents their transfer through the porins in the 
outer membrane of Gram-negative bacteria; thus making them inactive against this group of 
microorganisms (Nicolosi et al., 2010). Their principal use is to treat infections caused by 
Gram-positive cocci, such as infections caused by methicillin-resistant S. aureus (MRSA); 
and against anaerobic pathogens, such as the toxin-producing Clostridium difficile (Sköld, 
2011). 
Finally, an important last-generation group of antibiotics corresponds to glycylcyclines, 
represented by tigecycline (Olson et al., 2006). Tigecycline, approved for clinical use in 
2005, is a derivative of minocycline (tetracycline-group member) that possess a high activity 
against pathogens that are hard to treat, such as MSRA, vancomycin-resistant enterococci 
(VRE), Acinetobacter baumannii and extended-spectrum β-lactamase (ESBL)-positive 
pathogens (Noskin, 2005). Compared with polymyxins, tigecycline is less toxic and, in most 
patient populations, it is not necessary to adjust the dosage (Stein and Craig, 2006). Due to 
these features, tigecycline has the potential to be used in several clinical areas. The chemical 
scaffold of tigecycline (Figure 12) includes the classical structure of tetracyclines, where a t-








Figure 12. Chemical structure of tigecycline. The 9-t-butylglycylamido is indicated in the 
figure (adapted from Olson et al., 2006). 
 
Tigecycline has been approved for treating complicated intra-abdominal infections, 
complicated skin infections and adult complicated-pneumonia (Stein and Babinchak, 2013). 
This new-generation drug is still under study in order to analyse where and when it should be 
















1.2.2.  Mechanisms of action 
Antibiotics have two different effects in bacteria, either slowing growth (bacteriostatic) or 
killing the bacteria (bactericidal) and they can be classified according to their mode of action 
against bacteria. Accordingly, as shown in the Figure 13, there are five main mechanisms of 
action: (i) inhibition of protein synthesis, (ii) interruption of the cell wall synthesis, (iii) 
inhibition of an important metabolic pathway, (iv) interruption of nucleic acids synthesis and 
(v) destabilisation of cellular membranes.  
Figure 13. Schematic summary of the mechanisms of action of antibiotics. (i) Inhibition of 
protein synthesis, (ii) interruption of the cell wall synthesis, (iii) inhibition of an important 
metabolic pathway, (iv) interruption of nucleic acids synthesis, (v) destabilisation of cellular 











1.2.2.1.  Inhibition of protein synthesis 
Living and growing, among others functions, requires the use and supply of new proteins. In 
both type of cells, prokaryotic and eukaryotic, the synthesis of proteins, called translation, is 
a process in which the ribosomes are the subcellular structure responsible for carrying out 
this function. Nevertheless, prokaryotic and eukaryotic ribosomes are sufficiently different to 
allow antibiotics to effectively attack the bacterial (reviewed by Guilfoile, 2007). In bacteria 
the ribosome is a nucleoprotein complex, where two-thirds of them comprise RNA and one-
third protein. They are called 30S (small) and 50S (large) subunits (reviewed by Walsh, 
2003). In turn, the small subunit contains about 20 proteins and a 16S rRNA while the large 
subunit is formed by 30 proteins, a 23S rRNA and a 5S rRNA (reviewed by Walsh, 2003). 
Macrolides, such as erythromycin, binds selectively and reversely to the bacterial ribosomes, 
thus providing bacteriostatic activity (reviewed by Sköld, 2011). The erythromycin interacts 
with the 23S rRNA of the large subunit, blocking the polypeptide translation, interrupting the 
production of mature proteins (Schlünzen et al., 2001). Tetracyclines and glycylcyclines are 
bacteriostatic drugs that bind to the 30S ribosomal subunit, specifically to the 16S subunit, 
blocking the binding of the incoming aminoacyl-tRNAs (Tritton, 1977). Glycylcyclines have 
a higher affinity than tetracyclines, presumably because they differ in their binding 
orientation with the 16S subunit (Olson et al., 2006). Aminoglycosides represent another 
group of antibiotics that works by interrupting the biosynthesis of proteins in bacteria. Their 
activity is based on their ability to bind to the 16S rRNA of the 30S subunit (Moazed and 
Noller, 1987). Interestingly, unlike the other antibiotics that affect the protein biosynthesis, 
the aminoglycosides possess bactericidal activity as they induce alterations on the bacterial 
cells, such as sodium and potassium leakage, and later also to large biomolecules, finally 
leading to bacterial death (reviewed by Sköld, 2011). Chloramphenicol, a bacteriostatic drug, 




ribosome (reviewed by Sköld, 2011). A summary of the main antibiotics that affect the 







Figure 14. Antibiotics that block the synthesis of proteins (adapted from Walsh, 2003). 
 
1.2.2.2.  Interruption of the cell wall synthesis 
Both Gram-negative and Gram-positive bacteria possess a peptidoglycan (PG) layer as a 
component of their cell wall that confers resistance against osmotic lysis. This bacterial wall 
(Figure 15) is composed of a scaffold of long polysaccharide chains, which are cross-linked 
between themselves by peptides (reviewed by Sköld, 2011). To create the PG layer, there has 
to be enzymatic crosslinking of the glycan strands (transglycosylation) and of the peptide 
strands (transpeptidation) (reviewed by Walsh, 2003). In the enzymatic transpeptidation, 
catalysed by enzymes called penicillin-binding proteins (PBPs), so-called because they are 
the target of penicillin and other β-lactams, a pentapeptide attached to a monosaccharide 
containing a diaminoamino acid with two D-alanines is transferred out through the cell 
membrane. Afterwards, the monosaccharide unit is aggregated in a growing chain of 
polysaccharide of the cell wall where the carboxyl member of the peptide can form a peptide 
bond with the diaminoamino acid added peptide of an adjacent polysaccharide chain, thereby 
producing a covalent link between two polysaccharide chains (reviewed by Sköld, 2011). 
The β-lactams drugs inhibit the transpeptidation reaction by binding to the PBPs as there is 











Blocking this important process of the microorganisms makes a newly produced cell wall 






Figure 15. Schematic representation of the structure and biosynthesis of the peptidoglycan in 
bacteria (modified from Walsh, 2003). PBPs: Penicillin-binding proteins. The target site of 
β-lactams agents is highlighted in red. The target of glycopeptides, D-Ala4-D-Ala5, is 






Another group of antibiotics that affects the biosynthesis of the cell wall are the 
glycopeptides. These antibiotic drugs cannot penetrate through the outer membrane of Gram-
negative, thus they are effective only against Gram-positive pathogens (Van Bambeke, 
2006). The mechanism of action does not involve inactivation of key enzymes of the cell 
wall biosynthesis, but functions by binding to units that form the PG at the D-Ala4-D-Ala5 
tails (Figure 15) (reviewed by Walsh, 2003). This binding of glycopeptides leads to the 
interruption of the crosslinking reactions finally producing cell wall lability and bacterial 
lysis (Kahne et al., 2005). 
 
1.2.2.3.  Inhibition of an important metabolic pathway 
Folic acid is an important coenzyme that is essential for many biochemical reactions which 
occur inside all the cells. Differentially, bacteria have the ability to synthetize their own folic 
acid while humans need to get this vitamin from their diet (reviewed by Guilfoile, 2007).  
This difference permits the use of certain drugs that exclusively affect the pathway of folic 
acid synthesis of bacteria, avoiding any damage to human cells. The sulfonamides represent 
a group of drugs which interrupt the biosynthesis of folic acid in bacteria. Sulfonamides, 
currently represented by sulfamethoxazole, is administrated with trimethoprim, in a 
combination called co-trimoxazole (reviewed by Sköld, 2011). They are still widely used 
because they are cheap and effective (Ho and Juurlink, 2011). These drugs act synergistically 
at different levels in the same pathway, where sulfamethoxazole inhibits the enzyme 
dihydropteroate synthase (DHPS) in the folate synthesis process while trimethoprim blocks 
the dihydrofolate reductase (DHFR), which is the enzyme responsible for providing the 
pyrimidine thymilydate for DNA synthesis (Figure 16). The dihydropteroate is produced 
assembling GTP and p-aminobenzoate (PABA). As sulfonamide is a structural analogue of 










Figure 16. Schematic representation of the bacterial biosynthetic pathway of the folic acid 
(modified from Walsh, 2003). 
 
Trimethoprim prevents the enzymatic conversion of dihydrofolate (DHF) into 
tetrahydrofolate (THF). This inhibition occurs because trimethoprim is a structural analogue 
of the folic acid pterin motif and thus produces competitive inhibition of the DHFR enzyme 
(reviewed by Guilfoile, 2007; Sköld, 2011). Despite their effectiveness and selectivity, the 
use of co-trimoxazole has been threatened by the increase in resistant-pathogens during 
recent years and by the toxicity of the sulphomanide component (reviewed by Walsh, 2003; 
Sköld, 2011).  
 
1.2.2.4.  Interruption of the nucleic acids synthesis 
The replication of nucleic acids (DNA and RNA) are key processes necessary for living and 
growing, both in humans and bacteria. This action makes them an ideal target to inhibit 
pathogens. The replication of DNA is carried out by a group of enzymes, called 
topoisomerases, of which there are four members in bacteria. The different processes that 




these topoisomerases (Andriole, 2005). The functions of each topoisomerase in bacteria are 
different, topoisomerase I is responsible for relaxing negative supercoils, topoisomerase II 
(also called DNA gyrase) introduces negative supercoils and relaxes positive supercoils, 
topoisomerase III decatenates replication intermediates and bind dimers of DNA, and 
topoisomerase IV decatenates DNA and eliminates positive and negative supercoils (Pan and 
Fisher, 1997; Walsh, 2003). In general terms, the mechanism of action of fluoroquinolones is 
by affecting the changes in the conformation of the DNA necessary for the normal cell 
functioning.  The quinolones act by promoting degradation of the bacterial DNA by binding 
to the enzyme-DNA complexes of DNA gyrase and topoisomerase IV, leading to the death 
of the cell (reviewed by Hooper, 1999). In general, the activity of quinolones correlates with 
inhibition of DNA gyrase in Gram-negative (Figure 17) and with blocking the topoisomerase 
IV enzyme in Gram positive microorganisms (reviewed by Oliphant & Green, 2002).  
 
Rifampicin is an antibiotic which acts in a different nucleic acid than quinolones (Figure 17). 
This antibiotic corresponds to a RNA polymerase inhibitor, hence affecting bacterial growth. 
The effect of rifampicin is due to its ability to bind to the RNA polymerase of prokaryotic 
organisms, which is a large and complex enzyme formed by five peptide subunits (reviewed 
by Sköld, 2011). This structure is composed by a core tetramer of αββ’γ subunits and a σ 
subunit which is dissociable and that is in charge of direct the core polymerase to transcribe 
specific genes (reviewed by Walsh, 2003). Rifampicin binds to the β subunit in an allosteric 
site blocking the elongating RNA chain, producing a final inhibition of the bacterial 
transcription process (Campbell et al., 2001). The corresponding mammalian RNA 











Figure 17. Antibiotics that block DNA and RNA replication (adapted from Walsh, 2003). 
 
 
1.2.2.5.  Destabilisation of cellular membranes 
Polypeptide antibiotics, such as polymixin B and polymixin E (colistin), were available for 
use in the 1960s but their usage was stopped owing their nephrotoxicity. However, due to the 
dramatic increase of outbreaks caused by MDR-Gram-negative pathogens worldwide, their 
use has been reconsidered as an option for treating infections caused by these 
microorganisms (Kwa et al., 2008). Polymixin B and colistin are pentacationic molecules 
that have a bactericidal activity; the variation between them is just one aminoacid (Figure 
18). Their activity is due to their chemical nature which allows them to act as outer-
membrane-inserting cationic hydrophobic polypeptides (reviewed by Walsh, 2003). Their 
activity is similar to detergents, increasing the permeability of the cell membranes, leading to 
cell death (Kwa et al., 2008). This mechanism of action involved a first step of electrostatic 
binding between the cationic polymixin and the anionic LPS of the Gram-negative bacteria, 
leading to the distortion of the cell membrane (reviewed by Falagas & Kasiakou, 2005). This 
disturbance is due to polymyxins displace magnesium (Mg+2) and calcium (Ca+2) which are 
the responsible for stabilizing the LPS macromolecule (Kwa et al., 2008). The final result of 






intracellular content and, consistently, cell lysis (Schindler and Osborn, 1979). However, as 
mentioned before, these molecules are toxic for humans. Polymyxins are toxic to humans as 
they affect the renal system (nephrotoxic). There have been some advances in this field, 
making some modifications in the structure of colistin, trying to avoiding their noxious 
effects. One example corresponds to polymixin B nonapeptide (PMBN) that lacks the fatty 
acid tail. This change ensured that PMBN is 15 times less toxic than polymixin B, when was 
tested in mice (reviewed by Vaara, 2010). Because of this important side effect, it is 
compulsory to evaluate their use considering both risks and benefits for the patient. Further 
studies in order to understand the mechanism of nephrotoxicity and focus in decrease this 




Figure 18. Chemical structure of polymyxins. A: Polymyxins B; B: Colistin. The different 












1.3.  Mechanisms of antibiotic resistance 
Throughout history, whenever a new antibacterial drug is introduced, clinically significant 
resistance appears. Antibiotic-resistant bacteria can be selected in a hospital environment 
much faster than in the community, owing to the fact that in the hospitals there is an 
intensive and constant exposure to antibiotics. This exerts a selective pressure leading to the 
survival of those bacteria which had acquired the resistance mechanism(s) to face this 
pressure (reviewed by Walsh, 2003). The three major mechanisms of resistance in clinically 
important bacteria are: (i) enzymatic inactivation, (ii) efflux and impermeability, and (iii) 
replacement or modification of the antibiotic target. 
 
1.3.1.  Enzymatic inactivation 
This mechanism of resistance involves the production of enzymes which can either destroy 
or modify antibiotics. This is the most important and widely spread mechanism of resistance, 
specifically in β-lactams-resistance (Bush and Mobashery, 1998).  
 
1.3.1.1.  β-lactamases 
The hydrolysis mediated by β-lactamases corresponds to the most important mechanism of 
resistance to β-lactams (Palzkill, 2013). These enzymes hydrolyse the four-member β-lactam 
ring, producing an inactive β-lactam derivative (Bush, 1989). They are traditionally 
classified according either by their functional features or their primary molecular structure. 
According to their amino acid sequences, there are four main classes of β-lactamases, of 
which classes A, C and D are active-site serine enzymes (Bush & Mobashery, 1998; Bush & 
Jacoby, 2010). Briefly, the serine acts as a reactive nucleophile, attacking the β-lactam ring 




hydrolysis reaction, releasing the intact serine-β-lactamase and an inert β-lactam derivative 
(Figure 19) (Massova and Mobashery, 1998; Walsh, 2003). 
 
Figure 19. Enzymatic inactivation of β-lactams by serine- and zinc-β-lactamases (adapted 
from Walsh, 2003).  
 
In the case of the class B β-lactamases, they have a zinc ion in their active site, thus they are 
called metallo-β-lactamases (MBLs) (reviewed by Walsh, 2003). The MBLs use zinc to 
activate a water molecule and catalyse its incorporation to the β-lactam ring, producing an 
inactive product (Palzkill, 2013). The functional classification of β-lactamases is based on 
their catalytic properties which gives the chance to relate them to their clinical impact. A 
summary of the classification of β-lactamases is shown in Table 1. 
 
1.3.1.2.  Aminoglycoside modifying enzymes. 
Aminoglycosides represent another group of antibiotics that are inactivated through two 
main mechanisms of resistance: enzymatic modifications and decrease in aminoglycosides 




modifications in their chemical structure by the addition of different kind of substituents, 
interrupting their antibacterial activity by blocking the binding between the antibiotic and the 
ribosomes (reviewed by Walsh, 2003). There are three families of aminoglycoside modifying 
enzymes (AMEs). The inactivation of aminoglycosides can be achieved through the activity 
of kinases such as O-phosphotransferases (APHs), O-adenyltransferases (ANTs) and N-
acetyltransferases (AACs) that are present in both Gram-negative and Gram-positive 
pathogens (reviewed by Wright, 1999). The APHs enzymes catalyse the addition of a 
phosphate group to the molecule of aminoglycoside, while the ANTs kinases incorporate an 
acetyl member to the chemical scaffold and finally, the ANTs enzymes add an AMP group 
to the molecule of aminoglycoside (reviewed by Walsh, 2003; Wright, 1999). These 
enzymatic-modifications lead to produce chemical modified drugs, which bind poorly to 
ribosomes and where the uptake of aminoglycosides also fails, leading to high level 










Table 1. Classification of β-lactamases. A: Classification according to Bush & Jacoby, 2009; 
B: Classification proposed by Bush, Jacoby & Medeiros, 1995; NI: not included (Table 
















Common name Substrates Examples 
1 1 C Cephalosporinase Cephalosporins AmpC 
          1e NI C Cephalosporinase Cephalosporins CMY-37 
2a 2a A Penicillinase Penicillins PC1 
2b 2b A Cephalosporinase Penicillins, early 
cephalosporins 
TEM-1 
2be 2be A Cephalosporinase Penicillins, cephalosporins 
and monobactams 
SHV-2 









2c 2c A Carbenicillinase Penicillins, carbenicillin CARB-3 
2ce NI A Carbenicillinase Cefepime, carbenicillin RTG-4 
2d 
 
2d D Cloxacillinase Penicillins, including 
cloxacillin and oxacillin 
OXA-10 
2de NI D Cephalosporinase Extended-spectrum 
cephalosporins 
OXA-11 
2df NI D Carbapenemase Carbapenems OXA-23 
2e 
 
2e A Cephalosporinase Cephalosporins CepA 
2f 2f A Carbapenemase All β-lactams currently 
available 
KPC-2 
3a 3 B (B1, B3) Metallo-β-lactamase All β-lactams excluding 
monobactams 
VIM-1 
3b 3 B (B2) Metallo-β-lactamase Preferential hydrolysis of 
carbapenems 
CphA 




1.3.2.  Efflux and impermeability 
This mechanism represents the second major route of antibiotic resistance. The active efflux 
is mediated by transmembrane proteins, which act like pumps that export antibiotics, often 
against a gradient of concentration (reviewed by Walsh, 2003). By bioinformatic analysis, 
there are four main families of efflux pumps described that can extrude antibiotics. The first 
three families are drug-protons antiporters classified as part of the major facilitator subfamily 
(MFS), the small multidrug regulator (SMR) family or the RND (resistance/nodulation/cell 
division) superfamily (reviewed by Van Bambeke et al., 2000). The MFS subfamily 
members can extrude amphiphilic substrates (mono- or dicationic molecules), including 
antibiotics such as tetracyclines, fluoroquinolones, rifampicin, chloramphenicol and 
aminoglycosides (reviewed by Van Bambeke et al., 2000; Walsh, 2003). The SMR family 
includes small proteins of 12-kDa. They can expel lipophilic and multicationic substrates 
such as tetracyclines and erythromycin. The last proton-dependant group, the RND 
superfamily, can extrude a wide range of substrates, such as tetracyclines, glycylcyclines, 
fluoroquinolones, erythromycin, rifampicin, β-lactams, chloramphenicol and 
aminoglycosides (reviewed by Van Bambeke et al., 2000). The second major class of efflux 
pumps, the ABC family, are ATP-dependent systems. They can eliminate molecules from 
the intracellular environment through hydrolysis of ATP, thus is a mechanism that needs 
energy (reviewed by Walsh, 2003). Their substrates include tetracycline, fluoroquinolones, 
macrolides, rifampicin, chloramphenicol and aminoglycosides (reviewed by Van Bambeke et 
al., 2000). Besides efflux mechanisms, pathogens can modify the expression of some 
specific porins in the cellular membrane(s), preventing the uptake of noxious compounds. In 
the case of aminoglycosides, besides the activity of the AMEs, another mechanism of 
resistance is represented by impermeability, specifically by reduced aminoglycosides uptake. 
In this case, the reduction of the uptake of these drugs can confer resistance in 




uptake may reflect loss of respiratory chain components, leading to reduced bacterial growth 
and confers low-level of resistance, producing isolates of low clinical impact (Taber et al., 
1987; Acosta et al., 2000). However, other members of the cell envelope, different from the 
respiratory chain components, may be involved in the decreased uptake of aminoglycosides, 
such as the olipeptide-binding protein (OppA). This protein is the periplasmic component of 
a major oligopeptide permease system, which could participate in the transport of 
aminoglycosides in E. coli K-12 (Acosta et al., 2000). Specifically, kanamycin-resistant E. 
coli K-12 mutants express low levels of OppA (Acosta et al., 2000); whereas E. coli K-12 
mutant, which produces higher levels of this protein, are more susceptible to 
aminoglycosides (Kashiwagi et al., 1992). Nevertheless, the role of OppA in the resistance to 
aminoglycosides is controversial as, according to Nakamatsu et al., the OppA protein and the 
Opp system do not have a direct role in the aminoglycoside uptake and sensitivity in E. coli 
K-12. This can be explained by mutations that affect different components of the bacterial 
physiology, specifically those that affect the intracellular polyamines pool which control, at 
the posttranscriptional level, OppA expression and then the activity of aminoglycosides in E. 
coli K-12 (Nakamatsu et al., 2007).  
Another example is constituted by carbapenem-resistance in A. baumannii. In this case, it is 
well known that carbapenems enter the periplasmic space through a porin called CarO. In the 
case of some carbapenem-resistant strains, they lack this protein, blocking the entry of the 
antibiotics and impeding their binding to the target proteins (Mussi et al., 2007). 
 
1.3.3.  Replacement or modification of the antibiotic target 
These mechanisms of resistance are represented by the ability of drug-resistant bacteria to 
alter the antibiotic target to insensitivity while also preserving its essential cellular function. 




methicillin through the production of a β-lactamase but are resistant by the acquisition of the 
mecA gene, which encodes a new PBP, called PBP2a, that is a bifunctional 
transglycosylase/transpeptidase (Hiramatsu et al., 2001; Song et al., 1987). β-lactams have a 
low binding affinity for this PBP2a making S. aureus resistant to all kinds of β-lactams 
(reviewed by Walsh, 2003). Another mechanism of antibiotic-resistance that belongs to this 
classification group is vancomicin-resistance. There are two main pathogens which share the 
same mechanism of resistance to vancomycin, S. aureus and enterococci (Hughes, 2003). 
This mechanism involves the change of the acyl-D-Ala4-D-Ala5 end of the precursor of PG 
by acyl-D-Ala4-D-lactate5. This change in the structure of the precursor of the PG produces a 
decrease of 1000-fold in the affinity of vancomycin for its target (reviewed by Reynolds and 
Courvalin, 2005).  
In some macrolide resistance, mutations in the DNA gyrase gene leads to the methylation of 
the 23S rRNA preventing the binding of macrolides to their target (reviewed by Guilfoile, 
2007). On the other hand, cotrimoxazole resistance is mediated with the bypass of the 
normal metabolic pathway; a mutation in a plasmid-encoded gene of DHFR is responsible 
for producing a new variant of this enzyme, which confers resistance to trimethoprim 
(Amyes and Smith, 1974). Sulfamethoxazole resistance is achieved by mutations in the dhps 
gene that leads to the generation of a new variant of the dihydropteroate synthase (DHPS) 
that confers resistance to sulfamethoxazole (Amyes and Smith, 1974). Finally, the 
mechanism of resistance to polymyxins implies the modification of the structure of the cell 
wall via reduction of the LPS. Specifically, changes in the lipid A of the LPS controlled by 
PmrA/PmrB regulatory system, leads to modifications in the charge of the LPS, impeding 






1.4.  Genetic basis of the antibiotic resistance 
Antibiotic-resistance can either be innate or be an acquired characteristic. The innate 
resistance to an antimicrobial is due to the natural characteristics of a specific 
microorganism, such as the intrinsic resistance to vancomycin in E. coli. However, the 
acquisition of antibiotic-resistance occurs by different genetic mechanisms that allow the 
spread of genes that confer this phenotype. The mechanisms of resistance acquisition include 
mutations and capturing of exogenous genes (Giedraitienė et al., 2011; Hawkey, 1998). A 
summary of the genetic mechanisms involved in the acquisition of antibiotic resistance is 
shown in Figure 20. 
The most common mutations are mainly related to the alteration of the target molecules, 
such as in the case of the quinolone-resistance, where the mutations interfere with the 
binding of the antibiotic to the ribosome, blocking their antibiotic activity (Nikaido, 2009). 
Besides alteration of target molecules, mutations can contribute to antibiotic resistance 
through alterations of the promoter regions of antibiotic-resistance genes or affecting the 
genes that encode regulatory proteins of these determinants (Martinez and Baquero, 2000). 
An example of this effect of mutations is represented by the hyperproduction of AmpC β-
lactamase in E. coli, which is caused by promoter mutation that increases the transcription 
level of the ampC gene (Caroff et al., 2000). 
On the other hand, the acquisition of resistance genes represents an important feature 
associated with bacteria, which can allow them to capture and express genes that permit 
them to survive under antibiotic pressure. The capture of resistance genes can be mediated 
by three different mechanisms of horizontal gene transfer (HGT): conjugation, 






Figure 20. Mechanisms of resistance acquisition (Andersson and Hughes, 2010). 
 
Natural transformation is the process where bacteria can assimilate exogenous DNA from 
the external environment (Avery et al., 1944). This process is observed in many Gram-
negative and Gram-positive microorganisms. Conjugation is the process where mobile 
genetic elements (MGE) can be transferred between bacterial cells (reviewed by Toussaint 
and Chandler, 2012). Finally, transduction is the process where bacteriophages package host 
genes instead their own, and they transfer this exogenous genes into a new host (reviewed by 
Weinbauer and Rassoulzadegan, 2004). The HGT, mediated by any of the processes 





1.4.1.  Mobilome 
The Mobilome is defined as “all the mobile genetic elements (MGE) in a cell” (Siefert, 
2009). In other words, the MGEs are the agents of HGT (Toussaint and Chandler, 2012). The 
Mobilome is composed of plasmids and transposable elements (Siefert, 2009).  
The transposable elements group comprises transposons, insertion sequences (IS) and 
integrons, which, in turn, can be embedded into plasmids, allowing them to be mobilised 
between cells (Miriagou et al., 2006). They represent the most important genetic units 
involved in the mobilisation of genes, such as antibiotic-resistance genes, in bacteria. 
Transposons and IS (Figure 21) are genetic elements frequently associated with antibiotic-
resistance genes (Miriagou et al., 2006). 
 
1.4.1.1.  Insertion sequences 
An important part of the bacterial genome comprises IS elements (Figure 21). These MGEs 
are small (<2.5 kb), contain a transposase gene, an enzyme involved in their own mobility, 
and two inverted repeated sequences (IR) on the extremities (Mahillon and Chandler, 1998). 
These IR are short pieces of DNA (10-40 bp) whose functions are the binding of the 
transposase enzyme, cleavage and strand transfer reactions (reviewed by Mahillon and 
Chandler, 1998). They are composed by two functional domains. The domain A corresponds 
to the two or three terminal base pairs and is associated with cleavage and strand transfer 
reaction leading to the mobilisation of the IS whereas the domain B is involved in the 
transposase binding (Derbyshire et al., 1987). The IS play an important role in the process of 
antibiotic resistance. Many IS elements can regulate the expression of neighbouring genes. 
There are 25 IS elements described in A. baumannii to date (http://www-is.biotoul.fr, 
accessed on October 2013). An example of this effect is the case of ISAba1, which is widely 




gene, where this IS element provides a strong promoter for this carbapenemase gene, leading 
to its overexpression  and resulting, finally, in a carbapenem-resistant strain (Turton et al., 
2006a). ISAba1 has been associated with cephalosporin-resistance in A. baumannii, which 
has been detected upstream the blaADC-like gene, whereupon its expression increased (Corvec 
et al., 2003). Although the main mechanism of controlling gene expression by IS elements is 
providing a strong promoter, these MGEs can also contribute to antibiotic resistance by a 
different mechanism; specifically, it has been demonstrated that ISAba10 in A. baumannii 
can affect the production of a porin called CarO, involved in antibiotic uptake, by disrupting 
the gene due to its insertion in the open-read frame (ORF) of carO, affecting the entrance of 
antibiotics from the outside (Lee et al., 2011). 
 
1.4.1.2.  Transposons 
Transposons or “jumping genes” are a piece of DNA that encode functions related with their 
mobilisation and for an extra phenotype, such as, antibiotic resistance (Figure 21). There are 
two main classes of transposons according to their structure, class I or composite, and class 
II or complex transposons (Poirel et al., 2011). 
Composite transposons are bracketed by two separate IS elements (Figure 21). The genetic 
unit spanning from one IS to another is mobilised entirely, transporting additional genes, 
such as antibiotic resistance. An example of this type of transposons corresponds to the Tn5 
transposon that is composed by two copies of IS50 flanking three antibiotic resistance genes 
where one of the IS (right copy) copies encodes the transposase and an inhibitor of 
transposition, while the other copy (left copy) produces inactive proteins (reviewed by 















Figure 21. Schematic representation of transposons and insertion sequences (IS) (adapted 
from (Miriagou et al., 2006). 
 
The complex transposons, such as Tn2610, are bracketed by a pair of short IRs on their ends 
(Figure 21). These IRs, unlike IS, lack transposition activity. The essential genes related with 
the functions of transposition are encoded in the central zone of these genetic units 
(Yamamoto, 1989). In addition to the genes related with mobilisation, the central non-
repetitive zone of Tn2610 carries genes of antibiotic resistance, specifically a β-lactamase 








1.4.1.3.  Integrons 
Integrons were described during the 1980s (Stokes and Hall, 1989). They are genetic 
structures capable of capturing and expressing genes that are embedded in mobile units 
called gene cassettes (Hall and Collis, 1995). An integron is not mobilisable itself, owing to 
the fact that it does not contain a transposase gene in its structure, but they are intimately 
associated with transposons, which allows them to be mobilised (Cambray et al., 2010). 
These genetic units constitute the major vectors in multidrug-resistance in Gram-negative 
pathogens (Partridge et al., 2009). All integrons comprise an integrase gene, intI, and are 
divided into different classes according to their nucleotide sequences (Hall and Collis, 1998). 
The integrase corresponds to a site-specific tyrosine recombinase that catalyses the 
capture/excision of the gene cassettes, such as antibiotic-resistance genes (Stokes and Hall, 
1989) (Figure 22).  
In order to fulfil their role of capturing and expression of gene cassettes, integrons comprise, 
in addition to intI, an attI recombination site where the cassette is inserted/excised by a site-
specific recombination process between the attI and attC sequences and are transcribed from 



















Figure 22. Integration/excision of gene cassettes by integrons (Cambray et al., 2010). Pc: 
strong promoter; intI: integrase-encoding gene; attC: recombination site (cassette); attI: 
recombination site (integron). 
 
In addition to the classic integrons, another kind of integron-related genetic structures has 
been identified carrying antibiotic-resistance genes. These units, called ISCR-elements or 
complex-integrons, are characterised by the presence of a “common region” (CR) beyond the 




insertion sequences as they lack of terminal inverted repeated sequences and are mobilised 
by a rolling-circle transposition mechanism, permitting the transport of adjacent genes 
(Tavakoli et al., 2000). An example of this genetic unit is represented by ISCR1 elements 
related with cephalosporins resistance in A. baumannii. In this case, the blaPER-7 gene, which 
confers resistance to ceftazidime, is located in a complex-integron that carries the classical 
structure of integrons class 1 but differs in the 3’-end by the presence of the CR element, 
called ORF513 (Opazo et al., 2012a) (Figure 23).  
 
 
Figure 23. Schematic representation of an ISCR1-element. The classical structure of an 


















1.5.  The genus Acinetobacter 
The name Acinetobacter, from the Greek “akineto” which means “nonmotile”, was initially 
proposed in 1954 in order to separate them from the motile genus Achromobacter (Brisou 
and Prevot, 1954). After a study published by Baumann et al. (Baumann et al., 1968) the 
genus was accepted by the committee of Taxonomy of Moraxella and Allied Bacteria 
(reviewed by Peleg et al., 2008). Nowadays, the genus Acinetobacter includes Gram 
negative coccobacilli, with a DNA G+C content of 39 to 47%, nonmotile, catalase positive, 
strictly aerobic and oxidase negative (Bergogne-Bérézin and Towner, 1996). In the 
beginning, Acinetobacter was classified in the family Neisseriaceae, including one species, 
Acinetobacter calcoaceticus. Later, it was classified in the Moraxellaceae, which also 
includes Moraxella, Psychrobacter and related species (reviewed by Bergogne-Bérézin and 
Towner, 1996). This early classification was based on analysis of phenotypic characteristics 
which did not distinguish closely related species. Nevertheless, by the use of genotypic 
techniques, such as sequencing of the 16S rDNA, amplified fragment length polymorphism 
(AFLP) and sequencing of the rpoB gene, new species have been identified (Dijkshoorn et 
al., 2007; Peleg et al., 2008). A comprehensive list of Acinetobacter species is represented in 
Table 2. 
Most members of the genus Acinetobacter have been detected in human specimens (Table 
2), but not all are considered as clinically important. In this sense, A. baumannii, A. pittii and 
A. nosocomialis, named the “A. baumannii complex”, are responsible for causing 
opportunistic infections and outbreaks that involved Acinetobacter spp. mainly affecting 





Table 2. Taxonomic classification of the genus Acinetobacter (Dijkshoorn et al., 2007; 
Nemec et al., 2009, 2010, 2011; Towner, 2009; http://www.bacterio.net/acinetobacter.html, 
last accessed June 4th, 2014). 
Species Name Genomic species Source 
Acinetobacter calcoaceticus 1 Humans (including clinical specimens) and soil 
Acinetobacter baumannii 2 Humans (including clinical specimens) 
Acinetobacter haemolyticus 4 Humans (including clinical specimens) 
Acinetobacter junii 5 Humans (including clinical specimens) 
Acinetobacter johnsonii 7 Humans (including clinical specimens) 
Acinetobacter Iwoffii 8,9 Humans (including clinical specimens)  
Acinetobacter radioresistens 12 Humans (including clinical specimens), soil and cotton  
Acinetobacter ursingii  Humans (including clinical specimens) 
Acinetobacter schindleri  Humans (including clinical specimens) 
Acinetobacter parvus  Humans (including clinical specimens) and animals 
Acinetobacter baylyi  Activated sludge and soil 
Acinetobacter bouvetii  Activated sludge 
Acinetobacter towneri  Activated sludge 
Acinetobacter tandoii  Activated sludge 
Acinetobacter tjernbergiae  Activated sludge 
Acinetobacter gerneri  Activated sludge 
Acinetobacter beijerinckii  Humans, soil and animals 
Acinetobacter gyllenbergii  Humans (including clinical specimens) 
Acinetobacter pittii 3 Humans (including clinical specimens), vegetables and 
soil 
Acinetobacter nosocomialis 6 Humans (including clinical specimens) 
13TU Humans (including clinical specimens) 
Acinetobacter bereziniae 10 Humans (including clinical specimens), vegetables and 
soil 
Acinetobacter guillouiae 11 Humans (including clinical specimens) and soil 
13BJ, 14TU Humans (including clinical specimens) 
14BJ Humans (including clinical specimens) 
15BJ Humans (including clinical specimens) 
16 Humans (including clinical specimens) and vegetables 
17 Humans (including clinical specimens) and soil 
15TU Humans (including clinical specimens) and animals 
“Between 1 and 3” Humans (including clinical specimens) 






Table 2 (continued) 




















Trees (Populus x euramericana) 
Trees (Populus x euramericana) 






1.5.1.  Typing techniques 
Due to the difficulties to distinguish different Acinetobacter species, several techniques have 
been proposed for discriminating some or all members of this species; for example, four 
species (A. calcoaceticus, A. baumannii, A. pittii and A. nosocomialis) are very similar 
phenotypically, therefore they can only be distinguished by utilising molecular techniques 
(Evans et al., 2013). One proposed molecular method corresponds to the tRNA spacer 
fingerprinting, which is based on the amplification of the spacer regions of the tRNA (tDNA) 
clusters, which generates different electrophoretic patterns according to the specific 
sequences present on each species analysed (Ehrenstein et al., 1996; Evans et al., 2013).  
 
Another method corresponds to the sequencing of the 16S rDNA, which is based on the 
amplification and sequencing of the bacterial 16S rDNA (Ibrahim et al., 1997). In addition, a 




(rDNA) restriction analysis (ARDRA), in which, unlike the method described above, the 
amplification products are digested by different restriction enzymes (normally 5 enzymes), 
generating specific patterns for each species (Dijkshoorn et al., 2007). Another method based 
on the bacterial rDNA profile is the restriction analysis of the 16S-23S rDNA region, which 
examines the polymorphism within rRNA (rDNA) intergenic spacer regions present on the 
different Acinetobacter species (Dolzani et al., 1995). Amplified fragment length 
polymorphism (AFLP) analysis, in which the whole bacterial DNA is digested by restriction 
enzymes and then the fragments are PCR-amplified, generating specific patterns for each 
species (Dijkshoorn et al., 2007). This technique is also utilised to perform population 
structure studies within A. baumannii.  
 
Two methods based on the sequence of specific genes are the sequencing gyrB and rpoB 
genes. Both genes are considered as “housekeeping genes” and they represent appropriate 
candidates for species identification (Evans et al., 2013; Gundi et al., 2009; Peleg et al., 
2008). The “housekeeping genes” are constitutive genes that are necessary to maintain the 
basic cellular functions and are under purifying selection and slow evolution, and the 
changes on these genes are almost neutral (Enright and Spratt, 1999). The use of these 
methods has increased latterly, as they are rapid and reliable alternatives for identification. 
 
Another method proposed, is represented by the multilocus PCR and mass spectrometry 
(PCR/ESI-MS), where six “housekeeping genes” are amplified by PCR and their sequences 
are obtained by electrospray ionisation mass spectrometry (Ecker et al., 2006). Even though 
this method represents a rapid and reliable alternative, it needs special equipment and trained 





Despite the existence of several methods proposed, as mentioned previously, there is no 
universal consensus as to which should be used. The large number of methods that are used 
in different laboratories makes species-identification a problematic matter, as methods 
change in their specificity and sensitivity, making inter-laboratory comparisons unreliable 
(Evans et al., 2013). 
 
1.5.2.  Acinetobacter baumannii 
In epidemiological surveys, A. baumannii have been identified as the most frequent cause of 
infections among Acinetobacter species (reviewed by Evans et al., 2013). Although it has 
been considered that members of this genus are ubiquitous (Table 2), some being isolated 
from the environment and some form part of the normal human microbiota, A. baumannii 
has been recovered almost exclusively from nosocomial environment (reviewed by Towner, 
2009).  
 
A. baumannii is a microorganism with a low pathogenicity, in which the colonisation rate is 
higher than the infection (Dijkshoorn et al., 2007). Nevertheless, the crude mortality rates, 
associated with infections caused by this microorganism, are higher (between 8% and 43%) 
compared with other Acinetobacter species (between 7% and 18%) (Choi et al., 2006; 
Falagas et al., 2006; Seifert et al., 1994). Various factors contribute in the colonisation 
process, such as its adherence to the host cells, resistance to inhibitory agents and biofilm 
formation (reviewed by Dijkshoorn et al., 2007). Then, when the infection starts, it can be 
severe. Once the pathogen has colonised the patient, various factors play important roles in 
the infection process. Specifically, the LPS is a potent proinflammatory molecule, which 
stimulates an inflammatory signaling reaction through human Toll-like receptors (Erridge et 




et al., 2008). Additionally, iron-capturing mechanisms and resistance to human serum help 
A. baumannii to survive a long time in the blood during bloodstream infections (Dorsey et 
al., 2003; Jankowski et al., 1992). 
 
1.5.2.1.  Population structure of A. baumannii 
Diverse typing techniques, as AFLP, have shown genotypic diversity within A. baumannii 
(Diancourt et al., 2010). In this sense, multilocus sequence typing (MLST) is considered as 
the “gold standard” method to investigate the population structure and global spread of 
microbial pathogens. In this method, seven “housekeeping genes” are amplified and 
sequenced, generating diverse Sequence Types (STs) which are compared with those STs 
contained in an international database (Bartual et al., 2005; Diancourt et al., 2010). MLST 
studies have revealed the main structure of MDR-A. baumannii population, where 3 different 
International clones (ICs), also called “worldwide” (WW) lineages, are predominant 
(Diancourt et al., 2010; Higgins et al., 2010).  Indeed, the ICs-I, -II and -III are highly 
prevalent worldwide (Diancourt et al., 2010). However, according to Zarrilli et al., the 
population structure of A. baumannii, is changing, showing that it comprises at least nine 
different clonal lineages, which can disseminate in single institutions and/or worldwide 
(Zarrilli et al., 2013). Specifically, the IC-I and –II prevail internationally, while the IC-III 
other clonal lineages, such as the clonal complex 10 and clonal complex 15, are more 
prevalent in European hospitals (Zarrilli et al., 2013). Interestingly, each IC is related to a 
specific blaOXA-51-like enzyme; for example the IC-I is related to blaOXA-69, whereas the IC-II is 
associated with blaOXA-66 and the blaOXA-71 is present in isolates belonging to the IC-III 
(Zander et al., 2012), making it possible to relate the presence of specific blaOXA-51-like genes 
with some ICs (Pournaras et al., 2014), although this is still under discussion. It should be 
noted that the current population studies of A. baumannii have been performed by two 




standardise the methodology, in order to generate a more complete understanding of the 
dissemination of MDR ICs. 
 
1.5.2.2.  Clinical infections caused by A. baumannii 
A. baumannii is classified as a nosocomial pathogen involved in infections that mainly affect 
critically ill patients (Dijkshoorn et al., 2007). The fact that the colonisation is more common 
than infection, reflects that this microorganism possesses low pathogenesis (Dijkshoorn et 
al., 2007). However, some serious clinical infections are associated with this pathogen, in 
particular hospital-acquired pneumonia which is the most common infection caused by A. 
baumannii (McConnell et al., 2013). The ventilator-associated pneumonia (VAP) occurs 
mostly in critical patients who are receiving mechanical ventilation; factors such as longer 
periods of hospitalisation, longer time under mechanical ventilation, previous use of 
antibiotics (Howard et al., 2012), health care professionals with colonised hands and poor 
hygiene (Peleg et al., 2008) and contaminated care equipment all increase  the risk of 
developing this infection (Luna and Aruj, 2007). Importantly, the crude mortality associated 
with VAP caused by this pathogen has been reported to vary between 40% and 70% 
(Garnacho et al., 2003). Besides the VAP mentioned above, cases of community-acquired 
pneumonia associated with A. baumannii have been reported in Asia and Australia (Anstey 
et al., 2002). The crude mortality associated with this type of pneumonia ranges between 
40% and 60% (Leung et al., 2006), often being related with underlying host factors, such as 
alcohol consumption or chronic obstructive pulmonary disease (McConnell et al., 2013).  
 
In addition to pneumonia, A. baumannii is associated with bloodstream infections (BSI) in 
the intensive care units. The common sources of BSI are lower respiratory tract infections 




urinary tract infections have also been associated with BSI (McConnell et al., 2013). The 
crude mortality associated to BSI ranges between 28% and 43% (McConnell et al., 2013; 
Wisplinghoff et al., 2004).  
 
A. baumannii is also an important cause of burn and soft tissue infections, which are 
complicated to treat because the strains causing these infections are usually MDR and some 
antibiotics have a poor penetration to the infected sites (McConnell et al., 2013). 
Interestingly, A. baumannii has been associated with wound infections in military personnel. 
Specifically, in a study carried out at the US Army Institute of Surgical Research Burn 
Center, A. baumannii represented 22% of the microorganisms recovered from burn injuries, 
where 56% of the isolates were MDR (Keen et al., 2010); however, these infections are 
uncommon outside the military environment (Gaynes and Edwards, 2005). These infections 
are complicated to treat, as they could produce cellulitis and necrosis, requiring surgical 
removal of the infected tissue in addition to antibiotic therapy (Sebeny et al., 2008).  
 
Meningitis can also be caused by A. baumannii. This infection is commonly associated with 
patients recovering from neurosurgical procedures (McConnell et al., 2013); though, due to 
the limited number of studies, the rates of crude mortality are still unclear. It has been 
reported as high as 70% in a study published in 2007 (Metan et al., 2007). Finally, A. 
baumannii has been rarely identified causing endocarditis, where it was associated with 







1.5.2.3.  Genomic islands (GIs) 
In general terms, genomic islands (GIs) are defined as clusters of genes for which there is 
evidence of horizontal origins (Langille et al., 2010). There are different subtypes of GIs, 
classified according to the functions encoded by the genes they contain; for example 
“secretion islands”, antimicrobial “resistance islands” and “metabolic islands” (Langille et 
al., 2010). Consequently, the term “genomic island” has since been utilised as a general 
concept that referred to any cluster of genes, normally 10-200 kb in length that has been 
obtained through horizontal transfer (Hacker and Kaper, 2000). The basic structure of the 
GIs (Figure 24) includes the presence of direct repeat sequences flanking them, an internal 
region containing diverse genes encoding diverse features, functional and fragmented IS 
elements and other mobility-related elements, as well as a functional integrase gene, which is 
the responsible in the insertion or deletion of DNA in the central area of the GIs (Dobrindt et 
al., 2004). GIs are often integrated at tRNA genes in the bacterial chromosome (Figure 24) 
and often harbour functional or cryptic genes related to plasmid conjugation systems or 
phages involved in the mobilisation of the complete structure (Juhas et al., 2009). The life 
cycle of the GIs consists of the acquisition of the GI by horizontal transferring, integration of 
this element into the host chromosome by specific-recombination catalysed by an integrase, 
development of the GI by rearrangements, gene acquisition or loss of other mobile genetic 













Figure 24. General characteristics of GIs. DR: direct repeat; IS: Insertion sequence (Dobrindt 
et al., 2004). 
 
Even though the reason why GIs are often inserted into tRNA genes is still unclear, it is 
known that the insertion of these elements is catalysed by site-specific phage-like 
recombinases (integrases), which are usually present in the GI itself. Several of these 
integrases are related to the lambda, P4 or XerD families (Juhas et al., 2009; van der Meer et 
al., 2001), which may suggest the importance of the role of phages in the origin of GIs. An 
important characteristic of the GIs is that they have a lower G+C content in comparison with 
the core genome, reaffirming that the GIs presumably are horizontally acquired (Juhas et al., 
2009). 
 
The first GI in A. baumannii was characterised in 2006, in France, in an MDR-strain 
isolated. The strain,  named AYE, was resistant to β-lactams (excluding imipenem, 
piperacillin-tazobactam and ticarcillin-clavulanate), aminoglycosides, fluoroquinolones, 
chloramphenicol, tetracycline and rifampin (Fournier et al., 2006). This GI was specifically 
characterised as a resistance island (RI) as it harboured several genes of antibiotic and metal 
resistance (Fournier et al., 2006). This RI, termed AbaR1, is the largest GI described to date, 
as it has a length of 86-kb, encoding 88 predicted open-read frames (ORFs) of which 45 
were associated with resistance to antibiotics or biocides (Evans et al., 2013; Fournier et al., 




was inserted into the comM gene, which corresponds to an ATPase gene (Krizova and 
Nemec, 2010).  
 
Fournier et al. also analysed a susceptible strain, named SDF, which also had a disruption in 
the comM gene. In this case, a GI of 19-kb in length was detected, which contained 25 ORFs, 
none of which was associated with antimicrobial resistance (Fournier et al., 2006). 
Remarkably, the resistance genes identified in AbaR1 are likely to have originated in 
different species, according to the amino acid sequences of the proteins encoded by them, 
44% are likely originated from Pseudomonas spp., 34% from Salmonella spp., 17% from 
Escherichia spp. and 4% from different microorganisms (Fournier et al., 2006). This 
demonstrates that this RI is the result of successive acquisition of determinants of resistance 
from different hosts (Fournier et al., 2006; Schmidt and Hensel, 2004). Nowadays, several 
distinct RIs have been identified in A. baumannii strains, such as AbaR2, which was detected 
in an isolate collected in 2005 in Rome that harboured 17 genes, 7 of which are related to 
antimicrobial resistance (Iacono et al., 2008). Another RI was detected in an A. baumannii 
strain isolated in the USA, which contained a RI of 63-kb in length that harboured 8 
resistance genes (Adams et al., 2008). Interestingly, a strain collected in 1977 was found to 
contain a 63-kb RI highly similar to AbaR3, suggesting that these structures have been 
present in A. baumannii for a long time (Krizova and Nemec, 2010), reflecting the ability of 









1.5.1.1 Multidrug-resistant Acinetobacter baumannii 
The antibiotics available to treat infections caused by A. baumannii include broad-spectrum 
penicillins, broad-spectrum cephalosporins, monobactams, fluoroquinolones, 
aminoglycosides, polymyxins, carbapenems, sulbactam and tigecycline (reviewed by 
Towner, 2009). Nevertheless, the appearance of multidrug-resistant strains has increased 
during the last decade. In the case of A. baumannii, a multidrug-resistant (MDR) isolate is 
resistant to more than two of the following drugs: cephalosporins (ceftazidime or cefepime), 
carbapenems (imipenem or meropenem), ampicillin-sulbactam, fluoroquinolones 
(ciprofloxacin or levofloxacin) and -aminoglycosides (gentamicin, tobramycin or amikacin) 
(Peleg et al., 2008). Importantly, the increase of MDR isolates of A. baumannii worldwide is 
limiting the therapeutic options for treating infections caused by this MDR pathogen 
(Durante-Mangoni and Zarrilli, 2011).  
 
The MDR phenotype of A. baumannii is due to its remarkable ability to upregulate innate 
resistance mechanisms and to acquire exogenous resistance genes that play an important role 
in the development of this phenotype (Howard et al., 2012). 
 
There are several mechanisms of antibiotic resistance identified in A. baumannii that provide 
it with the ability to survive under the pressure from a wide range of antibiotics (Table 3), 





Table 3. Mechanisms of antibiotic resistance in A. baumannii (Bonnin et al., 2011a; Doi et 
al., 2004; Durante-Mangoni and Zarrilli, 2011; Evans et al., 2013; Higgins et al., 2013; 






Mechanisms of antibiotic resistance 
and classes of proteins involved 
Examples of specific enzymes, genes 
and targets involved 
Cephalosporins β-lactam hydrolysis 
Class C β-lactamase 
ESACs 
Class A ESBL 
 
 
Class D β-lactamase 
 
ADC-1, -2, -3, -4, -5, -6, -7. 
ADC-33,-56. 










Class A β-lactamase 
Class B MBLs 
 
CHDLs 




IMP-1,-2,-4,-5,-6,-11; VIM-1,-2; SIM-1; 
NDM-1,-2. 
OXA-23, -40, -58, -143 and -235 clusters. 
Confers resistance if there is a IS 
upstream of the gene. 
 Changes in OMPs 
CarO 
OprD-like OMP and 33-36 kDa OMP 
 
carO gene regulated by IS elements. 
Other OMPs involved in carbapenem-
resistance. 
Aminoglycosides Aminoglycosides-modifying enzymes 
(AMEs) 
16s rDNA methyltransferase 
AacC1/2; AadA; AadB; Ant1; AphA1; 
AphA6; AphA1B; Aac(6’)-Iad. 
ArmA 
Quinolones Target modification 
Gyrase subunit 
Topoisomerase IV subunit  
 
Mutation of the gyrA gene 
Mutation of the parC gene 
Rifampicin Drug modification 
Target modification 
Arr-2 
Mutation of the rpoB gene 
Cotrimoxazole Replacement of target 
Dihydropteroate synthase (DHPS) 
Dihydrofolate reductase (DHFR) 
 
Presence of sul1 and/or sul2 gene(s) 
Mutation of the folA gene 




Table 3. (continued) 
 
 
The mechanisms involved in the resistance to aminoglycosides include the presence of 
aminoglycosides-modifying enzymes (AMEs) which have been detected in integron class 1 
elements, including acetyltransferases, nucleotidyltransferases and phosphotransferases  
(reviewed by Peleg et al., 2008). Even though the presence of AMEs is the most prevalent 
mechanism of aminoglycosides in this pathogen, the methylation of the 16s rRNA, mediated 
by the ArmA enzyme, represents a new mechanism conferring a high-level resistance to all 
aminoglycosides currently available (Durante-Mangoni and Zarrilli, 2011; Yu et al., 2007).  
 
Resistance to tetracyclines and their derivatives (i.e. glycylcyclines) is mediated mainly by 
efflux pumps (Fluit et al., 2005). Two specific efflux pumps, TetA and TetB (Table 3), have 
been described in A. baumannii (Guardabassi et al., 2000; Ribera et al., 2003). The tet(A) 
gene has been detected in a transposon similar to Tn1721, which allows it to mobilise 
between different isolates (Ribera et al., 2003). Neither of them, TetA and TetB, affects 
tigecycline, which is expelled by the overexpression of the efflux pump AdeABC (Ruzin et 
al., 2007). In addition to AdeABC, AdeFGH and AdeIJK can expel a broad spectrum of 
antibiotics, including tigecycline (reviewed by Durante-Mangoni and Zarrilli, 2011). 
Antimicrobial 
drugs 
Mechanisms of antibiotic resistance 
and classes of proteins involved 
Examples of specific enzymes, genes 















AdeABC; AdeFGH; AdeIJK 
AdeM 
TetA; TetB 
Polymyxins Outer membrane modification Mutation in genes of lipid A synthesis and 




Quinolone-resistance is mediated by modifications of the DNA gyrase or topoisomerase IV 
by mutations in gyrA and parC genes that interfere with the binding between the 
antimicrobial drug and the target (reviewed by Peleg et al., 2008). It has been demonstrated 
that a single mutation in the gyrA gene at codon Ser-83 increases the MIC of ciprofloxacin 
from 2 mg/L to >32 mg/L (Spence and Towner, 2003). Additionally, an extra mutation in the 
codon Ser-80 of the parC gene leads to moxifloxacin resistance (Spence and Towner, 2003). 
Also, quinolones can be extruded by activity of broad spectrum RND-efflux pumps 
(Durante-Mangoni and Zarrilli, 2011; Higgins et al., 2004) and by the MATE pump AbeM 
(Su et al., 2005). 
 
Polymixin resistance is a new mechanism of resistance identified in A. baumannii as this 
drug have been reintroduced during the last few years for treating serious infections caused 
by MDR isolates. The mechanism of resistance includes the complete loss of the lipid A, 
which is a component of the LPS. This loss is a consequence of mutations within one the 
genes involved in the biosynthesis of the lipid A: lpxA, lpxC and lpxD (Moffatt et al., 2010). 
Moreover, polymixin resistance can be mediated by mutations in the PmrAB system. This is 
a system involved in sensing environmental pH, Fe3+ and Mg2+ levels, leading to altered the 
expression of genes involved in the biosynthesis of the lipid A (Adams et al., 2009). In 
colistin resistant A. baumannii strains, the expression of pmrA is increased, indicating that 
the mutations in this gene leads to a constitutive expression of PmrA, with the consequence 
that the strains become resistant to this drug (Adams et al., 2009). 
 
In the case of rifampicin, the major mechanism of resistance corresponds to mutations in the 
rpoB gene that encodes the β-subunit of RNA polymerase (McCammon et al., 2005; Telenti 




(RRDR) of the rpoB gene, interrupting the binding of the drug to the target site (Heep et al., 
2001; Tribuddharat and Fennewald, 1999). However, this mechanism has been identified 
mainly in M. tuberculosis, whereas the molecular basis of rifampicin resistance in A. 
baumannii and other Gram negative pathogens is typically due to the presence of the arr-2 
gene, which is usually part of integrons class 1 elements (Thapa et al., 2009; Tribuddharat and 
Fennewald, 1999). This additional mechanism of rifampicin resistance includes the presence 
of a rifampicin ADP-ribosylating transferase, named Arr-2, which inactivates rifampicin by 
ribosylation (Poirel et al., 2011). The fact that this gene is usually associated with integron 
class 1 structures, facilitates its spread among different isolates (Houang et al., 2003). 
 
The resistance to trimethoprim is due to mutations of the folA gene, which produces a 
dihydrofolate reductase (DHFR) that is not affected by trimethoprim, conferring resistance to 
this antibiotic (Mak et al., 2009). Additionally, the resistance to trimethoprim can be due to 
the presence of dfr genes, which can be present either on the chromosome or plasmids. These 
genes encode for trimethoprim-resistant DHFRs, obstructing the activity of this antibiotic 
(Sköld, 2000). Furthermore, integrons class 1 are very common among MDR strains of A. 
baumannii (Peleg et al., 2008). The 3’-conserved region of these genetic elements contains 
the qacE and the sul1 genes, which confer resistance to antiseptics and sulphonamides, 
respectively (Walsh et al., 2005). The sul1 gene encodes a dihydropteroate synthase (DHPS) 
that is not affected by sulphonamides (Antunes et al., 2005). Besides the sul1 gene, the sul2 
gene, which encodes for a variant of the DHPS, has been identified mediating the resistance 
to sulphonamides. This gene is mainly located on small plasmids, thus facilitating its spread 





In the case of β-lactams, the most prevalent mechanism of resistance is the enzymatic 
hydrolysis by β-lactamases. Intrinsically, all A. baumannii harbour an AmpC-like enzyme, 
called ADC (Acinetobacter-derived cephalosporinase) (Hujer et al., 2005). These enzymes are 
capable to hydrolyse cephalosporins, including extended-spectrum cephalosporins such as 
ceftazidime, when there is an IS element upstream of them, that increases their expression 
(Corvec et al., 2003). This represents the most common mechanism of cephalosporins 
resistance in A. baumannii. Nonetheless, the ADC enzymes do not possess activity against 
carbapenems and cefepime (Hujer et al., 2005). However, there are new ADC variants with 
activity against all cephalosporins, including cefepime. They include ADC-33 and ADC-56 
and have been designated as ESAC (extended-spectrum AmpCs) (Rodríguez-Martínez et al., 
2010; Tian et al., 2011). Unlike other ADC members, ESACs do not need the presence of an 
IS element upstream to promote the degradation of cephalosporins but they have two 
aminoacidic changes in the Ω-loop, increasing their spectrum of activity (Rodríguez-Martínez 
et al., 2010; Tian et al., 2011). Additional mechanisms of cephalosporin resistance are less 
prevalent in A. baumannii. These include the presence of class A ESBLs with activity against 
extended-spectrum cephalosporins, such as members of PER (Opazo et al., 2012a), GES 
(Delbrück et al., 2012), SHV, VEB, TEM and CTX-M families (Table 3) (reviewed by 
Durante-Mangoni and Zarrilli, 2011). Most of these ESBLs have been identified embedded in 
diverse types of mobile genetic elements. TEM-like ESBLs have been detected in the 
transposons Tn1, Tn2 and Tn3 (reviewed by Bonnin et al., 2011b). blaSHV-like genes have been 
identified bracketed by two copies of IS26, which may play a role in the mobilisation of these 
genes (Ford and Avison, 2004). Several types of genetic elements are related with mobilisation 
of CTX-M-like ESBLs, such as ISEcp1 and ISCR1 and also phage-related elements (Poirel et 
al., 2003; Poirel et al., 2008). In the case of VEB and GES-type ESBLs, their genes have 
formed part of integrons class 1 (reviewed by Poirel et al., 2008), while PER-like enzymes 
have been identified as part of a composite transposon called Tn1213 (Poirel et al., 2005a) and 




1.5.1.2 Carbapenem-resistance in Acinetobacter baumannii 
Carbapenems, such as imipenem and meropenem, are a potent group of β-lactams which 
represent one of the last options for treating infections caused by MDR A. baumannii due to 
their good activity and low toxicity (Evans et al., 2013; Towner, 2009). They have the 
broadest spectrum of activity within the β-lactam drugs (Nicolau, 2008). Nevertheless, as in 
other species, detection of carbapenem-resistant isolates has increased worldwide during the 
last decade. Even though carbapenem-resistance is mediated by various mechanisms and is 
the result of synergy between these mechanisms (Table 3), the most important is represented 
by enzymatic hydrolysis by carbapenemases (reviewed by Durante-Mangoni and Zarrilli, 
2011). The β-lactamases with carbapenemase activity include class D OXA-type β-
lactamases, metallo β-lactamases (MBLs) and class A β-lactamases (Table 3). 
 
The carbapenem-hydrolysing class D oxacillinases (CHDLs) are the most prevalent 
carbapenem-hydrolysing enzymes in A. baumannii and are represented by the OXA-type β-
lactamases. The CHDLs are divided in six different clusters, according to their nucleotide 
sequences (Evans et al., 2013; Higgins et al., 2013). These clusters are chromosomally 
encoded OXA-51-like and the acquired OXA-23-like, OXA-58-like, OXA-40-like (reviewed 
by Evans et al., 2013), OXA-143-like (Higgins et al., 2009) and OXA-235 (Higgins et al., 
2013).  
 
The OXA-51-like enzymes are mainly chromosomally encoded enzymes and are considered 
as intrinsic to A. baumannii (Turton et al., 2006a). The first member of this group was 
identified in Argentina in 2005 in carbapenem-resistant strains isolated from 1996 (Brown et 
al., 2005). There are nearly 100 variants of OXA-51-like enzymes identified, representing 




cluster have been identified in the chromosome of A. baumannii, some studies have detected 
OXA-51-like β-lactamase genes in plasmids (Pournaras et al., 2006; Vahaboglu et al., 2006). 
The role of the OXA-51-like enzymes in the resistance to carbapenems depends in their 
over-expression as a consequence of the presence of promoters in IS elements, such as 
ISAba1, upstream the blaOXA-51-like gene (Turton et al., 2006a).  
 
The very first OXA-type enzyme with carbapenemase activity was detected in 1993 in 
Edinburgh, in a strain collected in 1985. This enzyme was originally designated as ARI-1 
and later re-named as OXA-23 (Donald et al., 2000; Paton et al., 1993). There are four 
members of this cluster identified to date in A. baumannii, which have been detected both in 
plasmid and chromosome, while OXA-23-like enzymes have been detected in various 
members of Acinetobacter genus and also in Proteus mirabilis and Klebsiella pneumoniae 
(Bogaerts et al., 2006; Bonnet et al., 2002; Evans et al., 2013). Another OXA-type 
carbapenemase cluster is represented by the OXA-40-like enzymes. OXA-40 enzyme was 
detected in a Spanish hospital in 1997 (Bou et al., 2000). There are six variants identified to 
date, from which four have been detected in A. baumannii (reviewed by Evans et al., 2013). 
The OXA-58-like cluster is represented by four variants identified in A. baumannii. The first 
member, OXA-58, was identified in a strain collected in France in 2003 (Poirel et al., 2005). 
Lately, two new OXA-type enzymes clusters have been characterised. One is represented by 
the OXA-143-like cluster, with OXA-143 itself and OXA-182 as unique members. OXA-
143 was identified in 2009 in three isolates from Brazil, in a plasmid of ca. 30 kb (Higgins et 
al., 2009) while OXA-182 was identified in twelve isolates from Korea (Kim et al., 2010). 
Another new OXA-type carbapenemase cluster is represented by OXA-235-like enzymes, 
which includes the OXA-235, OXA-236 and OXA-237 enzymes. This new CHDLs were 
detected in plasmid from strains collected in the United States and Mexico between 2005 and 




al., 2013). The prevalent CHDLs predominantly have specific geographic distributions, 
whereas OXA-51-like enzymes are detected worldwide, OXA-23-like carbapenemases have 
been detected in the UK, France, Brazil, Iraq, Greece, Singapore, Italy, China (Opazo et al., 
2012b; Zarrilli et al., 2013). In addition, isolates of A. baumannii carrying variants of the 
OXA-40-like cluster have been frequently detected in Spain, Belgium, South Asia, Croatia, 
Brazil and Italy (reviewed by Zarrilli et al., 2013). Finally, members of the OXA-58-like 
cluster are often identified in plasmids and have been detected frequently among isolates 
collected worldwide (Pournaras et al., 2006).  
 
The class B carbapenemases are metallo β-lactamases (MBLs) which are able to hydrolyse 
all β-lactams available, excepting aztreonam, and are not inhibited by β-lactamase inhibitors 
(reviewed by Walsh et al., 2005). Despite their higher activity in comparison with CHDLs, 
their prevalence is lower in A. baumannii (reviewed by Peleg et al., 2008). Four groups of 
MBLs have been identified in carbapenem-resistant A. baumannii: VIM, IMP, SIM 
(reviewed by Peleg et al., 2008) and latterly NDM-like MBLs (Espinal et al., 2013; Kaase et 
al., 2011; Nakazawa et al., 2013) have been detected in this microorganism. Interestingly, A. 
baumannii has an important role in the origin and spread of NDM-like MBL. Even though 
the first description of blaNDM-1 was made in 2008 in Enterobacteriaceae isolates analysed in 
Sweden from a patient hospitalised in India; these enzymes have been also detected in A. 
baumannii, in particular blaNDM-1 and blaNDM-2 (Espinal et al., 2013; Rafei et al., 2014). The 
sequence of the blaNDM-1 gene suggests that it was originated in A. baumannii by the fusion of 
a pre-existing MBL gene with the AMEs gene aph6, resulting in a chimeric β-lactamase 





It is suggested that this fusion occurred in this microorganism due to the fact that the aph6 
gene is strongly related to A. baumannii and was firstly associated to this microorganism 
(Toleman et al., 2012). Secondly, the ISAba125 element, which is originally from A. 
baumannii, is frequently associated upstream of this MBL gene. Thirdly, the first European 
isolate of A. baumannii harbouring the blaNDM-1 gene, contained both blaNDM-1 and ISAba125 
transposon, with aph6 (Toleman et al., 2012). All these findings suggest that the first blaNDM-
like gene was generated in A. baumannii and their spread occurred from this microorganism. 
 
MBLs are commonly associated with integrons, representing a platform of dissemination of 
these determinants of resistance (Houang et al., 2003; Lee et al., 2012; Mishra et al., 2013; 
Tsakris et al., 2006). Like CHDLs, MBLs have a specific geographical distribution, where 
isolates carrying enzymes of the IMP family have been identified in Italy, Hong Kong, 
Singapore, Portugal, Brazil and Japan (reviewed by Zarrilli et al., 2013). In addition, 
members of the VIM-like family have been detected in isolates from Europe and the Far East 
(Tsakris et al., 2006; Zarrilli et al., 2013) whereas the SIM-1 MBL has been identified in 
isolates from South Korea (Lee et al., 2005). Finally, members of the new group of MBLs, 
NDM-like enzymes, have been detected in India, Germany, Algeria, Belgium, Bangladesh, 
Czech Republic, China, Egypt, Israel and the United Arab Emirates (reviewed by Zarrilli et 
al., 2013). 
 
In addition to MBLs and CHDLs, another group of carbapenemases have been detected in A. 
baumannii. These enzymes are rarely detected in this pathogen and are represented by class 
A β-lactamases (Table 3), specifically by GES and KPC enzymes (Bonnin et al., 2013; 




(Robledo et al., 2010) whereas GES-type carbapenemases have been identified in France and 
Belgium (Bonnin, et al., 2011b). 
 
Besides the presence of carbapenemases, there are other non-enzymatic mechanisms which 
play a role in the carbapenem resistance in A. baumannii. This mechanisms include 
modifications in the outer membrane proteins involved in the uptake of antibiotics from the 
external environment (Peleg et al., 2008). The loss of an OMP of 33-36 kDa or OprD-like 
OMP has been detected in carbapenem-resistant strains (del Mar Tomás et al., 2005). This 
loss is associated with the presence of OXA-51 associated with ISAba1 producing the 
carbapenem-resistant phenotype due to a synergistic effect between both mechanisms 
(Rumbo et al., 2013). Another OMP, CarO, a protein of 29-kDa, has been related with 
decreased susceptibility to carbapenems (Mussi et al., 2007). The expression of CarO is 
regulated by the activity of IS elements, such as ISAba1 and ISAba10, that can disrupt the 
carO gene, interrupting the expression of this OMP (Lee et al., 2011; Lu et al., 2009). 
Additionally, over-expression of efflux pumps, specifically ones that belong to the RND 
family, such as AdeABC (Nemec et al., 2007), AdeFGH and AdeIJK (Coyne et al., 2010), 
contribute to the efflux of a broad spectrum of antibiotics, including carbapenems. High 
levels of resistance are associated with the activity of efflux pumps plus the presence of 
carbapenemases (reviewed by Evans et al., 2013). 
 
1.5.1.3 Epidemiology of MDR-Acinetobacter baumannii 
As mentioned previously, among the ICs, the IC-II is the most prevalent, where the blaOXA-66 
has been frequently detected in Asia and South America (reviewed by Evans et al., 2013). 
Additionally, ICs have been detected recently in strains from Europe, North America and 




carbapenems (reviewed by Durante-Mangoni and Zarrilli, 2011). In Latin America, few 
countries possess national surveillance programs for the collection of data of antimicrobial 
resistance, making it difficult to estimate prevalence and evolution of this phenomena 
(Okeke et al., 2005). In this sense, the SENTRY Antimicrobial Surveillance Program, 
initiated in 1997, represents the most important source of information about antibiotic 
resistance in Latin America. According to this programme, Acinetobacter spp. causes the 
7.2% of the bloodstream infections, the 17.7% of pneumonia, the 9.9% of the skin and soft 
tissue infections in hospitalised patients between 2008 and 2010 (Gales et al., 2012). In this 
study, both P. aeruginosa and A. baumannii showed the highest rates of resistance to almost 
all the drugs available, except to colistin, regardless of the geographic region studied. 
Importantly, there were significant increases in the imipenem resistance in Acinetobacter 
spp. (Figure 25). Specifically in Chile, Argentina and Brazil, there has been an alarming rise 
in the rates of imipenem resistance during the last years, rising from 10% or less of 














Figure 25. Variation in the imipenem resistance rates overtime in Acinetobacter spp. from 
Latin America (Gales et al., 2012). 
 
On the other hand, multiple outbreaks of MDR A. baumannii in Asian and Middle Eastern 
countries have been reported (Peleg et al., 2008). According to the SENTRY Program, the 
rates of carbapenem non-susceptible isolates are less than 25%, 40% for cefepime and 
ceftazidime, 40% for the association ampicillin-sulbactam and 45% for ciprofloxacin 
between 2001 – 2004 (Gales, Jones, & Sader, 2006). Isolates resistant to tigecycline and 
colistin have been identified in this region (Navon-Venezia et al., 2007). According to a 
study of 2011, the susceptibility of Acinetobacter spp. from Tawam Hospital, Al-Ain, UAE; 
decreased between 2004-2008 to imipenem, ceftazidime, ciprofloxacin, gentamicin and 
piperacillin/tazobactam, comparing with the period 1999-2002 (Al-Kaabi et al., 2011). 
Specifically, the susceptibility to imipenem decreased from 99.0% in the period 1999-2002 
to 32.5% during 2008 and the susceptibility to ceftazidime dropped from 66.3% in 2004 to 





1.6.  Aims of this project 
 
Due to the importance of the Mobilome in the acquisition of resistance genes; the objective 
of this thesis was to investigate the role of plasmids, ISs, transposons-like structures and 
ISCR1-elements in the acquisition of ceftazidime- and carbapenem-resistance in A. 
baumannii from Chile and the UAE. 
 
 To identify the isolates, collected from Chile and the United Arab Emirates between 
2007 – 2008, genotypically as A. baumannii by amplification of blaOXA-51-like and 
rpoB genes by the polymerase chain reaction (PCR). 
 
 To characterise the MDR-phenotype and analyse the clonal dissemination of 
carbapenem-resistant A. baumannii isolates collected between 2007 – 2008 from 
Santiago, Chile and Al Ain, UAE. 
 
 To detect and characterise the carbapenemases genes involved in the carbapenem-
resistance in isolates from Chile and the UAE 
 
 To identify mobile genetic elements mediating the carbapenem-resistance in isolates 
from Chile. 
 
 To characterise the mechanism of ceftazidime-resistance in A. baumannii isolates 







Chapter 2 Materials and Methods 
 
2.1.  Bacterial isolates 
Sixteen A. baumannii isolates, collected from three different hospitals in Santiago of Chile 
between 2007 – 2008 and previously classified as carbapenem non-susceptible, were studied. 
These isolates were provided by Dr. Patricia García (Catholic University Hospital), Dr. 
Andrea Sakurada (University of Chile Hospital) and Dr. Marcela San Martin (Barros Luco 
Hospital). The samples were initially identified as A. baumannii by phenotypic tests in each 
individual hospital. Additionally, two A. baumannii isolates from Al Ain in the United Arab 
Emirates, were studied. These samples were provided by Professor Tibor Pál.  
 
For species identification experiments, the type strain A. baumannii ATCC 19606 was 
utilised as a control. For minimum inhibitory concentration tests determinations, the control 
strains S. aureus NCTC 6571, P. aeruginosa NCTC 10662, E. coli NCTC 10418 and A. 
baumannii ATCC 19606 were used. A list of the strains studied and their epidemiological 
data is shown in Table 4. 
 
All isolates were sub-cultured on MacConkey agar (Oxoid, Basingstoke, UK) and incubated 
overnight at 37°C. Later, a single colony was transfer into nutrient broth (Oxoid, 
Basingstoke, UK) and incubated overnight at 37°C with agitation. Afterwards, 100µL of the 





Table 4. List of isolates studied in this work. H1: Catholic University Hospital; H2: 
University of Chile Hospital; H3: Barros Luco Hospital. ICU: Intensive care unit; IntCU: 
Intermediate care unit; ICUs: Intensive care unit (surgical); ICUn: Intensive care unit 



































































































2.2.  Media and chemical reagents. 
All media and antibiotic discs utilised in this work were purchased from Oxoid (Basingstoke, 
UK). Broths and agar were prepared following the manufacturer’s instructions. They were 
autoclaved at 121°C/15psi during 15min for sterilisation. The chemical reagents used in this 
work were purchased from Sigma-Aldrich Company (Poole, UK) unless stated otherwise. 
The saline solution was prepared by adding 0.8g of NaCl in 100mL of distilled water and 
autoclaved. 
 
2.3.  DNA extraction and PCRs 
The isolates were incubated in nutrient broth (Oxoid, Basingstoke, UK) overnight at 37°C 
with agitation. Later, the culture was transferred into MacConkey agar and incubated at 37°C 
for 18h. Afterwards, a loopful of bacterial colonies was added to 100µL of sterilised distilled 
water (SDW) and boiled at 100°C for 10 min. Then, the eppendorf tubes were centrifuged at 
13,000rpm (6,000g) for 2min and the supernatant was used as DNA template. For further 
experiments, the supernatants were stored at 4°C. 
 
All PCRs were performed in total volumes of 50µL. All reagents, except primers that were 
supplied by Eurofins MWG operon, were purchased from Promega (Southampton, UK). The 
volumes of each reagent per reactions were: 5µL of 10X buffer (200mM Tris-HCl, 500mM 
KCl), 1.5µL of 50 mM MgCl2, 1µL of 1mM dNTP mix, 0.5µL of 10µM forward primer, 
0.5µL of 10µM reverser primer, 0.25U/µL Taq polymerase, 1µL of DNA template and 40.25 
µL of SDW. The primers were either obtained from previously published work or designed 
using Primer3 software (http://bioinfo.ut.ee/primer3-0.4.0/primer3/). Reactions were carried 





After the PCR amplification, the products were separated by electrophoresis in 1.5w/v 
agarose gels prepared in 1X TAE buffer (40mM Tris-acetate, pH 8.0, 2mM EDTA). 
Electrophoresis was performed in horizontal gels units (Bio-Rad, UK) at 100V for 15min. 
After running, the gels were stained with GelRed stain (Biotium, USA) solution prepared 
diluting 50µL of GelRed in 100mL of 0.1M NaCl, and visualised using a GelDoc 2000 
system (Bio-Rad, Milan, Italy). 
 
For sequencing, the PCR products were purified using the Qiagen purification kit (Qiagen, 
UK) and 5µL of the purified product was mixed with 1µL of 3.2pmol primers for forward 
and/or reverse sequencing. The DNA sequencing was performed using an ABI 3730 
capillary sequencing instrument (Applied Biosystems, Warrington, UK) by the GenePool 
laboratory (Ashworth Laboratory, King’s Buildings, The University of Edinburgh, UK). The 
sequences obtained were analysed utilising the BLAST database of the National Centre for 
Biotechnology Information (NCBI) (http://www.ncbi.nlm.nhi.gov). Alignment of the DNA 
sequences was carried out with the Multalin software 
(http://www.toulouse.inra.fr/multalin.html) to check any change in the sequences.  
 
2.4.  Species identification 
Species identification was carried out by detection of the blaOXA-51-like gene (Hamouda et al., 
2010; Woodford et al., 2006) and by amplification and sequencing of a 350 bp section of the 
rpoB gene (Gundi et al., 2009).  
The primers used for detecting the blaOXA-51-like genes and the expected size were: 
OXA-51-F: 5’-TAA TGC TTT GAT CGG CCT TG-3’    
          353bp 




The set of primers utilised for the detection and sequencing of the 350bp portion of the rpoB 
gene were 
rpoB-F: 5’-TAY CGY AAA GAY TTG AAA GAA G-3’ 
rpoB-R: 5’-CMA CAC CYT TGT TMC CRT GA-3’ 
 
Where Y=C, T; M=A, C; R=A, G. 
 
2.5.  Disc diffusion tests 
Antibiotic susceptibility test were carried out on IST plates agar by the disc diffusion method 
following the British Society for Antimicrobial Chemotherapy (BSAC) guidelines (Andrews, 
2010, version 9.1) unless otherwise stated. The isolates were classified as susceptible, 
intermediate or resistant according to the BSAC guidelines. The antibiotics tested with the 
Chilean isolates were ceftazidime (CAZ), aztreonam (ATM), imipenem (IPM), meropenem 
(MEM), cefotaxime (CTX), gentamicin (G), amoxicillin/clavulanic acid (AMC), 
ciprofloxacin (CIP), cefepime (FEP), piperacillin/tazobactam (TZP) and tigecycline (TGC). 
The criteria used to analyse the susceptibility to tigecycline, amoxicillin/clavulanic acid, 
aztreonam and cephalosporins were those proposed by the Clinical and Laboratory Standards 
Institute (CLSI) (Jones et al., 2007).  The antibiotic tested with the Emirati isolates were 
imipenem, meropenem, cefotetan, rifampicin, aztreonam, chloramphenicol, cefoperazone, 
cefepime, cefotaxime and cefpodoxime. The Emirati isolates were previously tested against 








2.6.  Minimum inhibitory concentrations (MICs) determinations 
The Chilean isolates were tested for their susceptibility to imipenem and meropenem. 
Imipenem was used in its combination with cilastatin with a potency of 50% (Merck, Sharp 
& Dohme Ltd, Hertfordshire, UK), and meropenem with a potency of 99.8% (AstraZeneca, 
Cheshire, UK). The isolates were grown on MacConkey agar plates at 37°C for 18h. Later, 
the isolates were incubated overnight in 5mL of IST-broth at 37°C and 180rpm in an orbital 
shaker. Afterwards, the MICs were determined on IST agar plates by the double dilution 
method according to the BSAC recommendations (Andrews, 2010, version 9.1) utilising a 
Denley multipoint inoculator (Denley, Surrey, UK). For the isolates from the UAE, the same 
methodology was used exchanging the drugs tested by rifampicin (Sigma-Aldrich, Poole, 
UK) and ceftazidime (Sigma-Aldrich, Poole, UK).  
 
2.7.  Pulsed-field gel electrophoresis (PFGE) 
Isolates were typed by PFGE according to Seifert et al. (2005) with some modifications. 
 
2.7.1.  Plugs preparation 
The isolates were inoculated into 5mL of nutrient broth and incubated overnight at 37°C 
with agitation. Later, the isolates were suspended in to 3mL of suspension buffer (100mM 
Tris-HCl, 100mM EDTA, pH 8.0). Each sample was adjusted to an absorbance range of 1.7 
– 1.8 at 610nm, that represents a cell density of approximately 109 cells/mL. Then, 500µL of 
each suspension were incubated in a water bath at 55°C for 10min. Immediately, 25µL of 
10mg/ml proteinase K, 500µL of melted 1% CHEF genomic agarose (Bio-Rad, UK) and 1% 
of sodium dodecyl sulphate (Fisher Scientific, UK) dissolved in TE buffer (10mM Tris, 




tubes ten times. Later, the samples were transferred in to plastic moulds (Bio-Rad, UK) and 
were allowed to solidify at 4°C during 5min. 
 
2.7.2.  Cell lysis 
The plugs were extracted from the moulds and were placed into 50mL plastic tubes 
containing 5mL of lysis buffer (50mM Tris, 50mM EDTA, pH 8.0, 1% sarcosine) and 25µL 
of proteinase K (20mg/ml stock solution). Then, the samples were incubated for 2h at 55°C 
in a water bath. Later, the lysis buffer was removed and the samples were washed two times 
with SDW and three times with TE buffer for 15min/wash at 55°C in a water bath.  
 
2.7.3.  Enzymatic restriction and electrophoresis 
A slice of each plug (4mm approximately) was incubated with 10µL of 10X buffer A 
(Promega, Southampton, UK) and 90µL of SDW for 15min at 25°C in a water bath. Later, 
the reaction buffer was removed and replaced by enzymatic digestion buffer comprising 
88µL of SDW, 9µL of 10X buffer A and 30U of ApaI (Promega, Southampton, UK) 
restriction enzyme and each sample was incubated at 25°C for 18h. The enzymatic reaction 
was stopped by removing the enzymatic digestion buffer and adding 100µL of 0.5X TBE 
buffer (0.89M Tris, 0.89M boric acid, 20mM EDTA, pH 8.0). Afterward, the plugs were 
loaded on a 1% CHEF agarose gel (Bio-Rad, UK) dissolved in to 90mL of 0.5X TBE buffer 
and the electrophoresis was run on a CHEF-DRII apparatus (Bio-Rad, UK) at 6V/cm and 
14°C during 19h with switch times ranging from 5s to 20s. After the running, the gel was 






2.7.4.  Data analysis 
The gels were visualised using a GelDoc 2000 system (Bio-Rad, Milan, Italy) and the 
images were analysed by the BioNumerics v7.0 software (Applied Maths, Sint-Martens-
Latem, Belgium). The clusters analysis was performed by the unweighted pair group 
(UPGMA) method using a Dice coefficient of 1.5% for each band and optimization of 1.5%. 
A grouping percentage of ≥87% was chosen as the threshold to establish clonal relatedness.   
 
2.8.  Detection of β-lactamases genes 
Detection of blaOXA genes was carried out by PCRs. All primers utilised are listed in Table 5. 
 
Table 5. Primers used for detecting blaOXA-like genes. 1Woodford et al., 2006; 2Higgins et al., 
2013; 3Héritier et al., 2005a. 









































No IS upstream  975bp 






Detection of the groups of blaOXA-51-like, blaOXA-23-like, blaOXA-40-like and blaOXA-58-like genes was 
carried out using the primers listed on Table 5 according to Woodford et al (2006). Detection 
and sequencing of blaOXA-51-like genes was performed using the primers and conditions 
described by Héritier at al. (2005a). The pair of primers utilised for this PCR allowed the 
detection of IS elements inserted upstream the blaOXA-like genes. Detection of blaOXA-235 was 
performed according to Higgins et al. (2013).  
 
Detection of blaOXA-143-like group was carried out using the primers listed on Table 5 using the 
following conditions: 
 
Pre-denaturation  94°C for 5min  1 cycle 
Denaturation  94°C for 30s 
Annealing:  57°C for 40s  30 cycles 
Extension:  72°C for 50s 
Final extension: 72°C for 6min  1 cycle 










Detection of blaADC, blaPER-like, blaVEB-like, blaGES-like and blaNDM-like genes was carried out 
using the following primers: 
Table 6. Primers used for detecting blaADC, ESBLs and blaNDM-like genes. 1Ruiz et al., 2007a. 
































Detection of blaADC genes was carried out according to Ruiz et al. (2007a). Detection of 
ESBLs and blaNDM was performed using the primers listed on Table 6 and under the 
following conditions: 
 
Pre-denaturation  94°C for 5min  1 cycle 
Denaturation  94°C for 30s 
Annealing:  57°C for 40s  35 cycles 
Extension:  72°C for 50s 
Final extension: 72°C for 6min  1 cycle 




2.9.  Detection of Insertion Sequences (ISs) and ISCR-like elements. 
PCR amplification follow by sequencing were performed in order to analyse the genetic 
environment of the blaOXA-58 genes in the Chilean isolates. For this purpose, the primers 
utilised were SM2 (5’-AAGTGTCTATATTCTCACC-3’) (Poirel and Nordmann, 2006) in 
combination with the OXA-58-R primer. The SM2 forward primer aligns in an intergenic 
region upstream the blaOXA-58 genes, allowing the detection of any insertion element related 
with these genes. To analyse the downstream region, a PCR was performed utilising the 
OXA-58-F primer and the ISAba3-R primer (5’-ATGCTGCCTTTAAATGAAGCCA-3’). 
 
The PCRs were carried out under the following conditions: 
 
Pre-denaturation  94°C for 5min  1 cycle 
Denaturation  94°C for 30s 
Annealing:  55°C for 40s  35 cycles 
Extension:  72°C for 50s 
Final extension: 72°C for 6min  1 cycle 
Cooling:  4°C 
 
To detect and characterise the ISCR1 element, which carried the blaPER-like gene in the 
isolates from the UAE, PCR and sequencing were performed. The detection and 
characterisation of the integron class 1 portion of the ISCR1 element was performed as 





The detection of the orf513 gene was carried out by PCR using the following primers (Opazo 
et al., 2012a): 
 
ORF513-F: 5’-TCAAAGAGACGACTCTGTGATGGAT-3’   
          1022bp 
ORF513-R: 5’-TGACTCTTATCCAACGCTTTGGC-3’ 
 
A set of PCRs and sequencing were utilised in order to investigate the genetic environment 
and the sequence of the blaPER-like gene. The different combinations of primers were: 
ORF513-F with PER-R; PER-F with gst-R (5’-GTTCAGTGGCTTCCCCTTTT-3’) and gst-
F (5’-GAACGGCCTTCAGACTCAAA-3’) with Abau-R (5’- 
GGGTTTCCGAGAAGGTGATT-3’) (Opazo et al., 2012a). 
 
All PCRs were performed under the following conditions: 
 
Pre-denaturation  94°C for 5min  1 cycle 
Denaturation  94°C for 30s 
Annealing:  57°C for 40s  35 cycles 
Extension:  72°C for 50s 
Final extension: 72°C for 6min  1 cycle 





In order to investigate the association between the blaADC genes and insertion sequences 
upstream of them, a standard PCR and sequencing were performed using the following 
primers: 
FU:  5’- GCGCCGTGAATTCTTAAGTG-3’    
          360bp  
RU:  5’- AGCCATACCTGGCACATCAT-3’ 
 
The expected size, when there were no insertion elements upstream, was 360bp. On the other 
hand, if any insertion sequence was located upstream the blaADC gene, the product size 
varied, but was somewhat larger that 360bp.  
 
The PCR conditions were:  
 
Pre-denaturation  94°C for 5min  1 cycle 
Denaturation  94°C for 30s 
Annealing:  57°C for 40s  35 cycles 
Extension:  72°C for 50s 
Final extension: 72°C for 6min  1 cycle 








2.10.  Plasmid analysis 
In order to analyse the presence of the blaOXA-58 gene in plasmids in the Chilean strains, the 
plasmids were extracted using a commercial kit (Promega, UK). After the extraction, the 
plasmids were separate by PFGE at 6V/cm and 14°C during 20h with an initial pulse of 5s 
and a final pulse of 20s. Afterwards, the gels were stained in a GelRed solution for 30min 
and destained for 15min with SDW. Later, the plasmid bands were extracted from the gel 
and the plasmid DNA was purified using the Qiagen extraction kit (Qiagen, UK). The 
plasmid DNA extracted was used as a DNA template for PCR experiments. In order to detect 
any chromosomal contamination, a PCR using the 16S-rRNA primers previously described 
(Lin et al., 2009) was utilised. To determine whether the blaOXA-58 genes were plasmid-
located, standard PCRs using the primers previously described in this section, were utilised.  
 
2.11.  Gene expression analysis 
2.11.1.  RNA extraction 
The expression of the blaOXA-58 genes was studied by RT-PCR. The bacterial RNA was 
obtained by inoculating the isolates into nutrient broth and they were grown to an optical 
density of 0.5 – 0.8 at 600 nm. Later, the RNA was extracted with the RiboPureTM-Bacteria 
kit following the manufacturer’s recommendations (Ambion, UK). In order to avoid any 
contamination, the benches and gloves were sterilised using the RNAZap solution (Ambion, 
UK). After the extraction, the concentration of RNA was measured using a NanoDrop 
spectrophotometer, ND-1000. Finally, any DNA contamination was eliminated by 






2.11.2.  Reverse-transcription PCR (RT-PCR) and data analysis 
To analyse the expression of the blaOXA-58 gene, 100ng of the purified RNA were reverse 
transcribed in to cDNA and a PCR detecting the blaOXA-58 was performed using the Access 
RT-PCR System Kit (Promega, UK), using the primers described earlier in this section. 
After the PCR program, the samples were separated by electrophoresis and the band 



















Chapter 3 Results and Discussion 
 
3.1.  To identify the isolates, collected from Chile and the United Arab Emirates 
between 2007 – 2008, genotypically as A. baumannii by amplification of blaOXA-51-like and 
rpoB genes by the polymerase chain reaction (PCR). 
The Chilean isolates were primarily identified as A. baumannii by detecting the blaOXA-51-like 
genes by standard PCR (Evans et al., 2008). All the isolates from Chile, except Ab11, were 
positive for this gene. An example gel showing the amplification of the blaOXA-51-like genes is 






Figure 26. Example gel of amplification of the blaOXA-51-like genes by PCR. The isolate Ab11 
was negative for the detection of blaOXA-51-like. C+: positive control A. baumannii ATCC 
19606; L: 100bp DNA ladder.  
 
As shown in Figure 26, the isolate Ab11 was negative for the amplification of the blaOXA-51-
like gene, hence this isolate was discarded for further analysis. The PCR was validated using 
the strain type A. baumannii ATCC 19606 as a positive control. All the Chilean isolates were 
previously phenotypically identified as A. baumannii in each particular hospital, however, 
my result shows that the isolate Ab11 had been erroneously classified, which represents a 
problem for hospitals as they do not have a routine molecular identification protocol, and 






probably the real number of infections caused by A. baumannii is over-estimated. Therefore, 
it is necessary to implement new methods of species identification as the cases of outbreaks 
caused by MDR A. baumannii have been increasing during recent years, necessitating an 
accurate classification of this microorganism.  
 
In the case of the samples from the United Arab Emirates, they were previously classified as 
A. baumannii and they were primarily confirmed as such by detection the blaOXA-51-like genes, 






Figure 27. Detection of the blaOXA-51-like genes in the isolates from the UAE. C+: positive 
control A. baumannii ATCC 19606; L: 100bp DNA ladder. 
 
In summary, all the samples from the United Arab Emirates and 15 samples from Chile were 
initially identified as Acinetobacter baumannii, discarding the isolate Ab11 as it had not 
shown a band corresponding to the blaOXA-51-like genes. 
 
The amplification of the blaOXA-51-like genes has been considered a simple, rapid and reliable 
method for species identification as these are naturally occurring carbapenemases genes to 
A. baumannii (Turton et al., 2006b). Strains of A. baumannii, which are carbapenem 






susceptible also carry these carbapenemases genes, as they confer resistance to carbapenems 
only when a insertion element, such as ISAba1, is located upstream (Turton et al., 2006a), 
leading to overexpression of the gene.  
 
Even though the detection of the blaOXA-51-like genes has been considered a rapid and reliable 
method to identify isolates as A. baumannii, the detection of these genes only is not enough 
to conclude that an isolate corresponds to this species. In this regard, in 2013, Zander et al 
demonstrated that in three A. baumannii isolates obtained from South Korea, South Africa 
and Turkey, the amplification of the blaOXA-51-like genes was negative for the expected PCR 
product of 353bp as in the multiplex-PCR proposed by Woodford et al (2006). However, the 
samples were positive for larger amplicons when the blaOXA-51-like genes were amplified by 
the multiplex-PCR described earlier. Besides, the samples were classified as carbapenem 
susceptible, therefore the variation of the amplicon sizes was not due the presence of an IS 
element upstream the genes. The amplicons sizes varied from 1.2 to 1.6kb. After the 
sequencing of the PCR products, it was possible to identify the presence of two insertion 
sequences inserted within the blaOXA-51-like genes, which generate the change of the size of the 
amplification products. The analysis of the complete sequence revealed the presence of the 
blaOXA-66 gene interrupted by the ISAba15 and the presence of the blaOXA-51-like variant blaOXA-
78 disrupted by ISAba19 (Zander et al., 2013). In the case of the isolate Ab11 studied in this 
work, it did not show any amplification product, therefore the absence of a blaOXA-51-like gene 
and/or a variant disrupted by an IS element determined that it was discarded.  
 
Besides the variation of the structure of the blaOXA-51-like genes due the presence of insertion 
elements, some blaOXA-51-like variants have been detected in plasmids from Acinetobacter 
species other than A. baumannii. Specifically, Lee et al. (2012) studied the presence of 




which were not susceptible to carbapenems. All the isolates studied harboured the 
association ISAba1-blaOXA-51-like. The blaOXA-51-like variants identified were blaOXA-194 and 
blaOXA-138. Interestingly, a similar genetic structure harbouring the plasmid-borne blaOXA-82 
variant was found in an carbapenem-resistant A. baumannii isolate from Taiwan (Chen et al., 
2010). Comparing the plasmids that carry the blaOXA-51-like genes in A. baumannii with the 
plasmids present in A. nosocomialis and Acinetobacter genomic species “close to 13TU”, the 
plasmid sizes were similar, at 50kb. This finding indicates that the dissemination of these 
genes is probably either due by the mobilisation of this specific plasmid from different A. 
baumannii strains or the plasmids were disseminated among different clones of non-
Acinetobacter baumannii species or even this dissemination is due the clonal dissemination 
of Acinetobacter species other than A. baumannii.  
 
Due the fact that these genes can be found on plasmids from species other than A. 
baumannii, the detection of the blaOXA-51-like genes as a unique method for species 
confirmation is insufficient for species identification, making it necessary to use a 
complementary method in order to ensure that the isolates studied correspond to A. 
baumannii. Other secondary methods include gyrB multiplex PCR, amplification and 
sequencing of the rpoB gene, tRNA spacer fingerprinting, sequencing of the 16S rDNA, 
PCR analysis of the recA gene, sequencing of the intergenic rDNA region, among others 
(Evans et al., 2013). 
 
In order to ensure that the isolates corresponded to A. baumannii, species identification was 
confirmed by a second methodology, specifically by amplification and sequencing of a 





All the isolates analysed were positive for the 350bp amplicon. The sequences obtained 
showed a similarity of 99% with the sequence of the rpoB gene available in the NCBI 
database (Figure 28) (accession number HQ123410.2). 
 
Figure 28. Comparison of the rpoB gene of the Ab1 isolate with the sequence available in the 
NCBI database. Query: Nucleotide sequence of rpoB of isolate Ab1; Sbjct: Subject sequence 
in the NCBI database. 
 
 
The rpoB gene, which encodes an RNA polymerase β-subunit, possesses four hypervariable 
zones. Among these different regions, the highly variable zone of 350bp (zone 1) differs 
between closely related Acinetobacter species. Specifically, according to Gundi et al. (2009), 
zone 1 shows a similarity range of 88.3%-96.9% when A. baumannii, A. pittii and A. 
nosocomialis, are compared. This similarity range increases to 98%-100% when the 




the rpoB gene represents a reliable and rapid method for species identification, which can be 
complemented, with other methods, such as detection of the blaOXA-51-like gene. 
 
As all the samples analysed in this work for sequencing of the 350bp portion of the rpoB 
shared more than 99% of similarity with the sequence available in the NCBI database, 





3.2.  To characterise the MDR-phenotype and analyse the clonal dissemination of 
carbapenem-resistant A. baumannii isolates collected between 2007 – 2008 from 
Santiago, Chile and Al Ain, UAE. 
 
3.2.1.  Susceptibility tests 
The isolates were tested by the disc diffusion method against different classes of antibiotics 
including carbapemens, cephalosporins, aminoglycosides, penicillins, fluoroquinolones and 
glycylcyclines.  
 
3.2.1.1.  Chilean isolates 
All the Chilean isolates were resistant to ceftazidime, aztreonam, imipenem, cefotaxime, 
gentamicin, amoxicillin/clavulanic acid, meropenem, ciprofloxacin and cefepime (Figure 
29).  
 
Isolate Ab13, isolated from the Barros Luco Hospital, was the only isolate susceptible to the 
piperacillin/tazobactam combination. The rates of nonsusceptibility to 
piperacillin/tazobactam are one of the highest in the world (Peleg et al., 2008). According to 
the SENTRY Program, the percentage of susceptibility to piperacillin/tazobactam in Chilean 
isolates is 13.9% for the 2008-2010 period (Gales et al., 2012). The effectiveness of this 
antibiotic combination has been decreasing as the percentage of susceptibility to this drug in 






Figure 29. Disc diffusion test results for Chilean isolates (n=15). CAZ: ceftazidime; ATM: 
aztreonam; IPM: imipenem; CTX: cefotaxime; G: gentamicin; AMC: amoxicillin/clavulanic 
acid; MEM: meropenem; CIP: ciprofloxacin; FEP: cefepime; TZP: piperacillin/tazobactam; 
TGC: tigecycline.  
 
All the Chilean isolates were resistant to the cephalosporins tested (cefotaxime, cefepime and 
ceftazidime) (Figure 29). Specifically, the resistance to ceftazidime in Chilean isolates of 
Acinetobacter spp. was one of the highest in comparison with other Latin American 
countries during the 2008-2010 period (Gales et al., 2012). The susceptibility of A. 
baumannii to these drugs, as in the case of the majority of the other antibiotics, has been 
varying during the recent years. Specifically, the percentage of susceptibility to ceftazidime 
in isolates collected in Latin America, reached 29.0% in 1997, rising to 45.8% in 2001, 
showing an improvement in the activity of this antibiotic (Diomedi, 2005). However, during 
the 2008-2010 period in Chile, the susceptibility to this drug decreased to 15.2%, being less 
effective against A. baumannii (Gales et al., 2012). The isolates analysed follow this trend, 
as ceftazidime and other cephalosporins tested do not have any activity against them. 
Cephalosporins represents an important option to treat infections caused by this 


































resistance present in a specific geographic area. There are currently no studies oriented to 
analyse the mechanisms of cephalosporin-resistance in Chile. 
 
Furthermore, the samples were non-susceptible to the amoxicillin/clavulanic acid. There are 
no studies analysing the prevalence and mechanisms of resistance to this antibiotic 
combination in A. baumannii from Chile. Additionally, all the Chilean isolates were non-
susceptible to aztreonam. This drug can be an important alternative to treat infections caused 
by carbapenem-resistant A. baumannii as the antibacterial activity of aztreonam increases 
when is used in combination with polyamines, such as spermine and spermidine (Malone 
and Kwon, 2013). Specifically, the MICs of aztreonam alone (≥128 mg/L) decreased to the 
range 0.25-8 mg/L when was used in combination with polyamines. Importantly, this effect 
occurred when polyamines were used in combination with aztreonam and other β-lactams 
except ceftazidime and meropenem (Malone and Kwon, 2013). Even though the mechanism 
of action of polyamines is unknown, it has been suggested that as these molecules are 
cationic compounds, they can interact with the negative outer membrane of A. baumannii, 
increasing the permeability to aztreonam (Malone and Kwon, 2013). Although this is a 
recent study, this strategy can represent a valuable alternative to carbapenems.   
 
The isolates from Chile were resistant to gentamicin (Figure 29). According to the SENTRY 
Program, during the period 2008-2010, the percentage of susceptibility of A. baumannii to 
this drug was 41.8% in Chile (Gales et al., 2012). In a study that analysed a set of 487 
isolates of A. baumannii from Chile collected during the 1993-1994 period, the percentage of 
resistance to gentamicin reached 94% (Gonzalez et al., 2000), indicating an important 





Additionally in a study conducted by the SENTRY Program, the percentage of susceptibility 
to gentamicin in A. baumannii from Latin America was 30.7% during 2001 (Tognim et al., 
2004) whereas according to a report of the Chilean Society of Infectology (2012), the 
percentage of susceptibility of A. baumannii to gentamicin, was 48.7% in hospitalised 
patients. This percentage is higher than the figure informed in the SENTRY Program for the 
period 2008-2010, which was 41.8% (Gales et al., 2012). These differences might be 
because the study performed by the Chilean Society of Infectology included more samples 
(2135) and more hospitals (28) than the study of the SENTRY Program, which included 79 
isolates and 2 hospitals from Santiago, therefore, these results are more representative that 
those informed by the SENTRY Program. As showed previously, there are variations in the 
percentages of susceptibility to gentamicin, which makes necessary to perform more studies 
including more isolates and more medical centres through the country. 
 
The isolates collected from Chile were resistant to ciprofloxacin (Figure 29). The percentage 
of susceptibility, according to the SENTRY Program, to this fluoroquinolone in A. 
baumannii from Chile was 16.5% during the 2008-2010 period (Gales et al., 2012). 
Previously, the susceptibility to ciprofloxacin in A. baumannii from Latin America was 
28.3% in 2001 (Tognim et al., 2004). Additionally, in a larger study that included isolates 
collected between January and December 2012, the percentage of ciprofloxacin 
susceptibility in samples obtained from hospitalised patients from 28 Chilean medical 
centres was 22.9% (report of the Chilean Society of Infectology, 2012, unpublished). 
Compared with the 2008-2010 period, the isolates from Chile were less susceptible to 






Interestingly, Ab14 and Ab16 were not susceptible to tigecycline, as their inhibition zone 
diameters varied between 16 and 15mm, respectively. The criteria used to interpret the 
susceptibility to tigecycline is the one proposed by the CLSI (Jones et al., 2007) which 
considers an isolate as susceptible when the inhibition zone is ≥19mm, intermediate between 
15-18mm and resistant when the zone diameter is ≤14mm, whence the isolates were 
classified as intermediate. 
 
The report of the 2012 SENTRY Program did not included this antibacterial agent in its 
analysis. However, according to a report of the Chilean Society of Infectology from 2009, 
which included 840 isolates from Chilean hospitals, the percentage of susceptibility to 
tigecycline was 94.8%, representing the second most active drug against A. baumannii after 
colistin during this period (Silva et al., 2011). The susceptibility to tigecycline in Chile has 
varied dramatically after 2009 as according to a newer study carried out by the Chilean 
Society of Infectology in 2012, the percentage of susceptibility to tigecycline fell to 62.7% in 
A. baumannii collected from hospitalised patients (report of the Chilean Society of 
Infectology, 2012, unpublished). This variation may be due to the increase in the usage of 
this drug in the country as it represents a potent option to treat complicated infections caused 
by MDR A. baumannii. This marked difference in susceptibility values to tigecycline may be 
also due to the variability of the methods utilised in this study, making it necessary to 
standardize the methods employed among different centres.  
 
The Chilean isolates were non-susceptible to carbapenems (Figure 29). In accordance to the 
report of the SENTRY Program of 2001, the percentage of susceptibility to meropenem in A. 
baumannii from Latin America was 81.6% while to imipenem was 83.7% (Tognim et al., 




susceptibility to carbapenems in isolates from Chile decreased dramatically. Specifically, the 
susceptibility to imipenem was 47.4% and to meropenem was 46.8% (Gales et al., 2012). 
The imipenem-resistance has been significantly changing in Chile, while during the 1997-
1999 period, the imipenem-resistance was 0.0%, changing during the 2003-2005 period, 
when the imipenem-resistance was 6.2% and finally the rates of imipenem-resistance rose to 
50.0% during 2010-2012 (Gales et al., 2012). Nevertheless, the limitation of the SENTRY 
Program study of 2012, as in the case of other figures described above, is the number of 
medical centres and isolates analysed. In the report of the Chilean Society of Infectology of 
2012, which included a larger number of samples (2135) and hospitals (23), the 
susceptibility to imipenem in A. baumannii from Chile was 32.3% and to meropenem was 
26.9% (report of the Chilean Society of Infectology, 2012, unpublished). The rapid changes 
in the susceptibility to carbapenems in Chile represent a problem to treat infections caused 
by this microorganism. Even though the trend of carbapenem-susceptibility is clear in the 
country. It is necessary to get more information about this, including the study of more 
medical centres and more isolates. This is because the evolution of the carbapenem-
resistance is clearly rapid which makes it necessary to take immediate action, otherwise 
these potent drugs will become useless within a few years. 
 
In conclusion, the samples collected from Chile were classified as MDR as they were 
resistant to antipseudomonal cephalosporins (cefepime and ceftazidime), carbapenems 
(imipenem and meropenem), fluoroquinolones (ciprofloxacin) and aminoglycosides 





The MICs to carbapenems of the Chilean isolates to carbapenems were determined by the 
double dilution method according to the BSAC’s recommendations. The results are shown in 
the Table 7.  
 
According to the BSAC guidelines (Andrews, 2010), the MIC breakpoints to carbapenem are 
>8mg/L for resistant strains, between 4-8 for intermediate and ≤2mg/L for susceptible. The 
Chilean isolates analysed were categorised as imipenem-resistant, except the isolates Ab9 
and Ab15, which had MICs of 8mg/L, corresponding to intermediate. In the case of 
meropenem, the isolates Ab1, Ab2, Ab3 and Ab16 had MICs values higher than 8mg/L; in 
consequence, they were classified as meropenem-resistant. The remaining isolates were 
intermediate to meropenem (Table 7), as they MICs values to this carbapenem oscillated 
between 4 and 8mg/L.  
 
The MIC results showed a correlation between the disc diffusion tests performed and the 
double dilution diffusion test, as both methods classified the isolates as carbapenem-non-
susceptible. It is important to analyse the evolution of the carbapenem-resistance in Chile, 
since the number of isolates resistant to this potent class of antibiotics during recent years in 
this country has been increasing. Moreover, it is highly important to identify the genes 
involved in the carbapenem-resistant from this country. In this sense, according to the 
SENTRY Program  (Gales et al., 2012), the most prevalent OXA-type carbapenemase gene 
in South America during 2008-2010  was the blaOXA-23-like group, specifically in isolates from 
Argentina and Brazil. However, in the specific case of Chile, this trend was different, as the 





Table 7. Minimum inhibitory concentrations (MICs) to carbapenems of A. baumannii 























































3.2.1.2.  Emirati isolates 
According to the disc diffusion method, the isolates from the UAE were resistant to 
imipenem, meropenem, cefotetan, aztreonam, cefoperazone, cefepime, cefotaxime and 
cefpodoxime. However, the NM55 isolate was also resistant to rifampicin and ceftazidime, 
while the NM128 isolate was susceptible to both antibiotics. Both samples were previously 
characterised in the laboratory of Professor Tibor Pál in the UAE as ciprofloxacin and 
gentamicin resistant and, in turn, they were were tigecycline-susceptible. Thus, this drug 




to the definition of MDR proposed by Peleg et al. (2008), the Emirati strains were classified 
as MDR-A. baumannii as they were resistant to antipseudomonal carbapenems (imipenem 
and meropenem), fluoroquinolones (ciprofloxacin) and aminoglycosides (gentamicin).  
 
In the UAE, as in the rest of the world, the susceptibility rates to different classes of 
antibiotics decreased dramatically, specifically from the 1999-2002 period to the period 
2004-2008 (Al-Kaabi et al., 2011), when NM55 and NM128 were collected. It is necessary 
to perform more studies analysing the trends of antibiotic-resistance in the country, as there 
is a lack of national data, which is a key factor to improve the usage of antimicrobials. 
 
The difference in the ceftazidime-resistance between both strains was crucial and important 
to investigate, as they were collected from the same patient 4 months apart. This difference 
between them may be due to the ability of A. baumannii to develop resistance to all types of 
antibiotics. In this sense, the susceptibility to ceftazidime in 2004 was 66.3%, and dropped to 
31.6% during 2008 in Tawam Hospital (Al-Kaabi et al., 2011). This change could be due to 
the appearance of mechanisms of resistance that have not previously been identified in the 
UAE, such as production of uncommon ESBLs. 
 
The MICs of ceftazidime were 64.0mg/L for isolate NM55 and 0.2mg/L for isolate NM128. 
Moreover, the MICs of rifampicin were 32.0mg/L for isolate NM55 and 2.0mg/L for isolate 
NM128. Interestingly, the isolates were collected consecutively from the same patient 4 
months apart, showing an important difference in the pattern of ceftazidime-resistance, 
particularly as the more resistant isolate NM55 was collected first. As mentioned previously, 
the main mechanism of ceftazidime-resistance is the overexpression of the blaADC-like genes 




not present upstream the blaADC-like gene in both isolates, which had previously been 
determined by the laboratory of Professor Tibor Pál in the UAE and reconfirmed by myself, 
suggesting the presence of other, less common mechanisms of resistance. This could include 
the presence of ESBLs, the investigation of which formed the next objective of this thesis.  
 
The first sample (NM55) collected was resistant to ceftazidime, while the isolate collected 
later (NM128) was susceptible to this antibiotic, reflecting the ability to this microorganism 
to catch and/or lose genetic elements rapidly. The resistance to rifampicin also differed 
between both isolates, as the NM55 isolate was resistant to this drug whereas NM128 was 
susceptible. The mechanism of rifampicin-resistance that may explain this difference was 
investigated and the results are shown in the next objective of this thesis. The change in the 
susceptibility patterns of ceftazidime and rifampicin may be due to a change in the therapy 
plan, to which the patient was probably subjected. 
 
3.2.2.  Clonal distribution of A. baumannii 
The Chilean isolates were analysed by PFGE in order establish their clonal relationship. The 
geographic distribution of the three hospitals analysed is shown in the Figure 30. The 
Catholic University Hospital (H1) corresponds to a private medical centre, whereas the other 
two hospitals analysed (H2 and H3) are public centres and process a higher number of 










Figure 30. Geographic distribution of the hospitals from Santiago of Chile analysed. H1: 














Figure 31. Dendogram showing the genetic diversity of A. baumannii from Chile determined 
by PFGE. The hospital, hospital wards, year and source of isolation are shown in the figure. 
H1: Catholic University Hospital; H2: University of Chile Hospital; H3: Barros Luco 
Hospital. ICU: Intensive care unit; IntCU: Intermediate care unit; ICUs: Intensive care unit 
(surgical); ICUs: Intensive care unit (neurology); ITU: Intensive therapy unit. The broken 
line corresponds to the cut-off level (≥87%) used to define the PFGE clonal clusters. The 
clonal groups are highlighted in red. 
 
 
From the first hospital analysed (H1), two main clonal clusters were identified by PFGE 
(Figure 31). The first cluster comprises the Ab3 and Ab4 isolates from the same ward, 
whereas the second cluster includes the isolates Ab5, Ab7, Ab8 and Ab9, which were 
collected from three different hospital wards. The Ab1 isolate showed 85% similarity with 
the cluster formed by the Ab3 and Ab4 isolates, which indicates that the isolate Ab1 is 





















































































































with the other isolates obtained from this hospital. The presence of isolates that belong to the 
same clonal group in different wards may indicate that the strategy to control the 
dissemination of MDR clones, such as hand washing and surface disinfection, has failed in 
this hospital. It is now become increasingly important to perform a larger study of the 
prevalent clones in order to adjust the strategy needed to control the dissemination of these 
isolates within the hospital.  
 
The isolates Ab10 and Ab12, collected from the University of Chile Hospital (H2); showed 
79% similarity by PFGE (Figure 31). This indicates that they are probably not part of the 
same clonal group and they may have derived from different ancestors. This situation is 
similar to a study where 9 carbapenem-resistant A. baumannii isolates collected from the 
Aberdeen Royal Infirmary, Scotland, were analysed. The samples shared less than 80% 
similarity by PFGE and also harboured different blaOXA-51-like genes, such as blaOXA-51, blaOXA-
66, blaOXA-65, blaOXA-216, blaOXA-217 and blaOXA-89 (Lopes et al., 2012a). These results showed 
that the clinical situation in this clinical centre was in a state of constant evolution, where 
new variants strains were continuously arising; this could be a similar situation to the one 
that is occurring in the Hospital H2. 
 
Finally, the isolates Ab13 and Ab15 form part of the same clonal group from Barros Luco 
Hospital. The isolate Ab14 showed 85% similarity with Ab13 and Ab15, suggesting that 
they might share a common origin. Interestingly, they were isolated in different years from 
different hospital wards, which shows that these MDR-A. baumannii clones were transmitted 
and persistent within this hospital. Isolate Ab16 showed a low similarity with all the other 




with samples obtained from the Catholic University Hospital (H1), which may suggest that a 
common clone could be transferred between these hospitals.  
 
In conclusion, these results show the presence of clonally related MDR-isolates within the 
hospital H1, which might suggest that the strategy to prevent the spread of these isolates is 
not effective. Additionally, it is important to emphasize that the Ab16 isolate, collected in the 
hospital H3, shared a high similarity (80%) with the clonal group identified in the hospital 
H1, which may be a consequence of the transfer of colonised patients between hospitals in 
Santiago. These findings highlight the need to implement a surveillance network including 
the most important hospitals from the country. 
 
The isolates obtained from the UAE showed 92% of similarity by PFGE (Figure 32). The 
isolates shared less than 60% similarity with the first three classic European Clones, 






Figure 32. Dendogram showing the genetic diversity of A. baumannii the UAE determined 
by PFGE. CCU: Coronary care unit. The broken line corresponds to the cutoff level (≥87%) 
used to define the PFGE clonal clusters. EC1: European clone 1; EC2: European clone 2; 





































The isolates were considered isogenic as they were isolated consecutively from the same 
patient 4 months (first NM55 and NM128 later) apart and exhibited the similar PFGE 
patterns. These data suggest that these samples shared a common ancestor. Interestingly, 
despite the fact that they are isogenic, collected in the same year and ward, they have a 
different susceptibility pattern to ceftazidime. Specifically, NM55 was resistant to 
ceftazidime, whereas NM128 was susceptible to this drug. The reasons for this change are 
difficult to explain in an environment where cephalosporins, such as ceftazidime, are being 

















3.3.  To detect and characterise the carbapenemases genes involved in the carbapenem-
resistance in isolates from Chile and the UAE. 
 
The intrinsic genes belonging to the blaOXA-51-like group had previously been detected as a 
method to identify the isolates as Acinetobacter spp. These results are shown in the section 
3.1. However, is well known that individual members of the blaOXA-51-like group have a 
specific geographic distributions, related to epidemic lineages (Evans et al., 2008), thus 
making it necessary to know the sequence of the variants detected in Chile and in the UAE. 
 
3.3.1.  Chilean isolates 
The members of the OXA-51-like group identified in the isolates from Chile were OXA-51, 
OXA-219, OXA-67 and OXA-64. A comparative analysis of the aminoacid sequences of 
these carbapenemases is shown in the Figure 33.  
 
Figure 33. Multiple alignment of the OXA-51-like carbapenemases identified in the Chilean 




The OXA-219 β-lactamase possesses one change in comparison with the parental enzyme 
OXA-51. This change is at position 175, where leucine was replaced by valine (Figure 33). 
Both aminoacids are hydrophobic, so the tertiary structure is not radically affected. In the 
case of the OXA-64 enzyme, there are three changes compared with OXA-51 (Figure 33). 
The changes are T13A, A46G and V56A. The substitution of threonine by alanine in the 
position 13 is significant as it is a replacement of a hydrophilic amino acid for a hydrophobic 
residue, which may affect the structure of the enzyme. Finally, the OXA-67 enzyme has four 
changes in its amino acid sequence. It has the same change as OXA-64 in the position 13, 
where threonine is substituted by alanine. Additionally, it has two substitutions, in the 
positions 20 and 29 (Figure 33), where a hydrophilic amino acid (alanine) was substituted by 
a hydrophobic residue (threonine). Finally, another significant change is at position 202, 
where proline was replaced by leucine, this is an important change in the secondary structure 
as proline can disrupt alpha helix and β-sheets structures (Morgan and Rubenstein, 2013). 
 
The enzyme OXA-51 itself was identified in the isolates Ab5, Ab6, Ab7, Ab8 and Ab9, 
which were all collected in the hospital H1 (Figure 34). Additionally, this carbapenemase 
was also detected in the isolate Ab16 that was obtained in the hospital H3. The isolates Ab5, 
Ab7, Ab8 and Ab9 are part of the same clonal group (Figure 34), indicating that they may be 
derived from the same ancestor. Previously it had been shown by PFGE that isolate Ab6 
showed 81% similarity with the samples described above, while the Ab16 had 80% 
similarity with them (Figure 31). In addition, they also carry the OXA-51 β-lactamase, 
confirming that they are related. As in the case of the clonal analysis, the sequencing results 
of the OXA-51 enzymes confirm that the Ab16 isolate may have been transferred from 
hospital H1 to hospital H3. It is important to note that this is the first report of the OXA-51 





The enzyme OXA-51 itself was originally detected in isolates from Argentina collected in 
1996 that were resistant to carbapenems (Brown et al., 2005). Due to the close geographical 
relationship between Chile and Argentina, there is a high probability that some MDR-A. 
baumannii isolates could be transferred from one country to another, probably from 
Argentina to Chile as this enzyme was discovered much earlier in Buenos Aires (Brown et 
al., 2005). 
 
Some isolates that belong to the same clonal group carry different OXA-51-like variants. 
Specifically the isolates Ab13 and Ab15 are part of the same cluster but they carry the OXA-
67 and the OXA-64 enzymes, respectively. The same difference occurred in isolates Ab3 and 
Ab4, which were isolated from the hospital H1 and have 93% similarity by PFGE; however, 
they have different OXA-51-like variants, specifically OXA-219 and OXA-67, respectively 
(Figure 34). The determination of the clonal relatedness could be performed by different 
methods, such as PFGE or MLST; however, the sequencing of the blaOXA-51-like genes can 
represent a simpler and faster methodology. However, it has been shown that blaOXA-51-like 
gene sequencing correspond to MLST and sequence group typing, but not to PFGE (Zander 
et al., 2012).  
 
Additionally, as mentioned before, it is well known that some ICs or WWs are related with 
specific blaOXA-51-like variants (Evans et al., 2008). In this sense, a single-locus-based typing 
method, based in the sequence of blaOXA-51-like enzymes, has been proposed to assign A. 
baumannii isolates to ICs (Pournaras et al., 2014). Pournaras et al. conclude that this method 
classified accurately isolates of A. baumannii belonging to all major international clones; 





The OXA-51 itself has been identified in isolates from Chile and Brazil, which could not be 
related with any WW lineages, sharing just 77.9% similarity with the WW5 (Zander et al., 
2012). Furthermore, the OXA-219 variant has been related to the WW4, which was 
previously detected in Chile, and also in Turkey, Argentina, India, Germany and Brazil 
(Zander et al., 2012). Moreover, the OXA-64 variants have been identified in the WW7, 
which in turn has been identified in Latvia, Switzerland, Venezuela, Mexico, Colombia, 
Singapore and Germany (Zander et al., 2012). Finally, the OXA-67 variant has been 
previously detected in isolates from Argentina (Brown and Amyes, 2005). However, in order 
to characterise them accurately as part of specific international clones, more experiments are 
required, as a multiplex-PCR amplifying 3 “housekeeping genes”, csuE, ompA and blaOXA-51, 
termed 3LST (Turton et al., 2007), which corresponds to a rapid and reliable typing method. 
 
These results suggest that the MDR-isolates collected in Chile may belong to certain WW 
lineages that have been identified in other South American countries, such as in Argentina, 
Venezuela, Colombia and Brazil, suggesting the spread of these WW lineages among 
countries of the region. Nevertheless, more studies focused on the complete characterisation 
of the strains, such as the multiplex-PCR mentioned above, are necessary to conclude to 















Figure 34. Dendogram showing the genetic diversity and the OXA-51-like variants of A. 
baumannii from Chile determined by PFGE. H1: Catholic University Hospital; H2: 
University of Chile Hospital; H3: Barros Luco Hospital. ICU: Intensive care unit; IntCU: 
Intermediate care unit; ICUs: Intensive care unit (surgical); ICUs: Intensive care unit 
(neurology); ITU: Intensive therapy unit. The broken line corresponds to the cutoff level 











































































































































3.3.2.  Emirati isolates 
 
Both Emirati isolates analysed carried the OXA-64 β-lactamase (Figure 35). As they are 
classified as isogenic strains, this was an expected result. According to Zander et al. (2012), 
this variant is related with the clonal lineage WW7, which has been detected in some 
European countries and in Latin America. Additionally, isolates containing this OXA-51-






Figure 35. Dendogram showing the genetic diversity and the OXA-51-like variants of A. 
baumannii from the UAE determined by PFGE. The broken line corresponds to the cut-off 
level (≥87%) used to define the PFGE clonal clusters. EC1: European clone 1; EC2; 
European clone 2; EC3: European clone 3. 
 
The samples from the UAE presented a low similarity with the main WW clones (ECs in the 
figure), and also they did not show similarities in the sequences of their blaOXA-51-like genes as 
the WW1 to -3 correlate with OXA-69, OXA-66 and OXA-71 β-lactamases respectively 
(Zander et al., 2012).  Interestingly, this thesis is the first report of isolates containing the 
OXA-64 variant in Chile and in the UAE. According to the amino acid sequences, the OXA-



































WW3 clone (Evans et al., 2008). Nevertheless, it is necessary to perform further analysis 
such as MLST in order to determine the WW (IC) to which the isolates belong. 
 
 
3.3.3.  Acquired carbapenem-hydrolysing class D β-lactamases (CHDLs) 
It is well known that the resistance to carbapenems in A. baumannii is mediated mainly by 
the activity of OXA-type carbapenemases (Peleg et al., 2008). In this regard, the mere 
presence of the intrinsic OXA-51-like enzymes does not contribute towards the carbapenem-
resistance. Their specific contribution depends on its association with insertion sequences, 
such as ISAba1 upstream the blaOXA-51-like genes (Turton et al., 2006a), which provides a 
strong promoter. The presence of this association is investigated in the next aim of this 
thesis. On the other hand, the acquired CHDLs play a key role in the resistance to 
carbapenems in A. baumannii. Due to the above, the presence of acquired CHDLs, such as 
OXA-type carbapenemases, was carried out by PCR of their genes.  
 
The acquired CHDL present in the Chilean isolates were screened by the multiplex PCR 
proposed by Woodford et al. (2006). This multiplex PCR includes the OXA-51-like, OXA-
23-like, OXA-24-like and the OXA-58-like carbapenemases. An example gel of this PCR is 
shown in the Figure 36. The sizes of the products for each group are 353bp for blaOXA-51-like, 
501bp for blaOXA-23-like, 246bp for blaOXA-24-like and 599 for blaOXA-58-like. As two new groups of 
carbapenemases, OXA-143 and OXA-235, were described after the multiplex-PCR proposed 
by Woodford et al. (2006), they were screened by separate standard PCR using the primers 
and conditions proposed by Lopes (PhD Thesis in Biomedical Sciences, The University of 











Figure 36. Example gel of amplification of the acquired CHDLs by multiplex PCR. L: 100bp 
DNA ladder; +23: blaOXA-23-like positive control; +24: blaOXA-24-like positive control; +51: 
blaOXA-51-like positive control; +58: blaOXA-58-like positive control. 
 
The results of the multiplex PCR and the MICs of carbapenems are summarised in Table 8. 
The most prevalent acquired CHDL in the samples from Chile was the OXA-58 
carbapenemase, which was present in 12 of the 15 samples analysed (Table 8). In the case of 
the Emirati isolates, the presence of OXA-type carbapenemases was previously investigated 
in the laboratory of Professor Tibor Pál, in the UAE. Both samples, NM55 and NM128, were 
positive for the blaOXA-23-like as an acquired CHDL. These results were confirmed by myself 
using the specific primers for blaOXA-23-like genes proposed by Woodford et al. (2006) (Figure 


















Figure 37. Confirmation of the presence of the blaOXA-23-like gene by PCR. C+: positive 
control A. baumannii previously determined in our laboratory as blaOXA-23-like positive; L: 

















Table 8. OXA-type carbapenemases present in the Chilean isolates. H1: Catholic University 
Hospital; H2: University of Chile Hospital; H3: Barros Luco Hospital. CHDL: Carbapenem 
hydrolysing class D β-lactamase. 
















































































































The blaOXA-58-like genes have been previously identified in carbapenem-resistant isolates from 
South America, specifically in Argentina, Colombia, Bolivia and Venezuela (Higgins et al., 
2010; Lopes et al., 2013; Merkier et al., 2008; Opazo et al., 2012b). Even though the most 
frequent OXA-type carbapenemases detected in South America are OXA-23-like and OXA-
24-like, during 2007-2008 the case in Chile was different, as isolates containing enzymes of 
the OXA-58 group were more prevalent (Gales et al., 2012; Opazo et al., 2012b). The 
sequencing of the PCR products showed the presence of the OXA-58 enzyme itself, in the 
Chilean isolates (Figure 38).  
 
Figure 38. Comparison of the blaOXA-58-like gene of the Ab6 isolate with the sequence 
available in the NCBI database (http://www.ncbi.nlm.nih.gov/). Query: Nucleotide sequence 
of blaOXA-58-like of isolate Ab6; Sbjct: Subject sequence in the NCBI database. 
 
As shown in the Table 8, the MICs of carbapenems of the Emirati isolates that contained the 




harbour the OXA-58 enzyme. When the values of the MICs are compared between isolates 
that contain the OXA-64 variant as a common intrinsic enzyme (isolates Ab15, NM55 and 
NM128), the presence of the OXA-23-like carbapenemase is crucial for provide higher 
resistance to carbapenems, suggesting that the impact of OXA-23-like β-lactamase to the 
resistance to carbapenems is greater than the effect of OXA-58. In this sense, according to a 
study where the hydrolytic activities of different acquired OXA-type carbapenemases were 
analysed, it was determined that OXA-58 has the lowest activity in comparison with OXA-
24 and OXA-23 (Héritier et al., 2005b). Interestingly, when the blaOXA-58 gene was cloned 
into a commercial plasmid and then incorporated into a carbapenem-susceptible A. 
baumannii strain, the MICs of carbapenems were lower than when the natural plasmid 
harbouring the blaOXA-58 gene was incorporated into the same susceptible strain. Specifically, 
when the susceptible strain CIP70.10 was transformed with the natural plasmid containing 
the OXA-58 β-lactamase, the MICs of imipenem and meropenem were each 16mg/l. When 
the same strain was transformed using commercial plasmids that contain the same 
carbapenemase gene, the MICs of imipenem and meropenem were 0.5mg/l. These 
differences may be due to the presence of IS-elements, such as ISAba3, associated with the 
carbapenemase gene in the natural occurring plasmid, which could increase the expression of 
the gene, leading to the resistance to these compounds (Héritier et al., 2005b).  
 
 
The blaOXA-58-like gene was the most prevalent in the isolates studied in this thesis, which were 
collected during 2007-2008; however, in a study where 90 carbapenem-resistant A. 
baumannii collected between 2011 and 2012 from Chile were analysed, the most prevalent 
acquired OXA-type carbapenemase was OXA-23-like (Opazo Alexis A., Personal 
Communication, 2014). These differences represent an important change in the mechanisms 
of resistance to carbapenems, as OXA-23 has a higher hydrolytic activity than OXA-58, and 




may be the result of the mobilisation of resistant strains from neighbouring countries where 
these enzymes have been previously detected.  
 
According to the Table 8, the MICs values of meropenem of the isolates Ab1, Ab2 and Ab3, 
are the highest among the Chilean samples, in that they do not contain any known acquired 
OXA-type carbapenemase; however, they harboured the OXA-219 enzyme as a member of 
the intrinsic OXA-51-like enzymes. According to Zander et al. (2012), some carbapenem-
resistant isolates, which harboured the OXA-219 enzyme, were also positive for the presence 
of ISAba1 upstream the blaOXA-219 gene and did not possess an extra CHDL. Interestingly, 
the isolate Ab15 did not show any acquired CHDL and harboured the OXA-64 as member of 
the intrinsic OXA-51-like group (Table 8). Unlike the isolates Ab1, Ab2 and Ab3, which did 
not contain any extra CHDL and possessed the OXA-219 variant, the MIC of imipenem was 
comparatively lower; being intermediate, according to the BSAC guidelines (Andrews, 
2010), whereas its MIC of meropenem was higher and classified it as meropenem-resistant 
(Table 8). These differences may be due the presence of an extra non-enzymatic mechanism 
of resistance, such as loss of porins and active efflux (Peleg et al., 2008), which may be 
affecting the activity of meropenem. 
 
In the case of the Emirati isolates, the blaOXA-23 gene has been previously detected in 
countries from the Arabian Peninsula. Specifically, A. baumannii isolates carrying the OXA-
23 enzyme have been identified in Bahrain, the UAE and Saudi Arabia (Mugnier et al., 
2010; Zowawi et al., 2013). In the case of the isolate from Bahrain, it was collected in 2008 
and the genetic platform associated with the blaOXA-23 comprised the ISAba1 element which, 
in turn, was identified on a plasmid of ca.130kb (Mugnier et al., 2010). Interestingly, the 




that was collected two years before the isolation of the Bahraini sample (Mugnier et al., 
2010). Additionally, another isolate that harboured the blaOXA-23 gene, collected in 2006 from 
the UAE, presented a different genetic platform that comprised Tn2006 and was embedded 
in the chromosome (Mugnier et al., 2010).  
 
In the case of Saudi Arabia, the analysis of 56 isolates obtained from Riyadh, collected 
between 2010 and 2011, showed that the 53.6% harboured the blaOXA-23 carbapenemase 
(reviewed by Zowawi et al., 2013). Furthermore, of 132 Acinetobacter isolates from the 
eastern province of Saudi Arabia, 79.5% of the samples carried the blaOXA-23 gene (reviewed 
by Zowawi et al., 2013). The results shown above represent a novel detection of the blaOXA-23 
gene in the Arabian Peninsula, specifically in the UAE (Opazo et al., 2012a). The 
association of this gene with any insertion sequence is analysed in the next aim of this thesis. 
According to Zowawi et al. (2013), the OXA-23 enzyme is the most prevalent in the Arabian 
Peninsula, representing one of the most important mechanisms of carbapenem-resistance in 









3.4.  To identify mobile genetic elements mediating the carbapenem-resistance in 
isolates from Chile. 
 
3.4.1.  Association between ISAba1 and blaOXA-51-like. 
This section analysed the association of the resistance genes detected with mobile genetic 
elements, such as insertion sequences, plasmids, etc. As shown previously, the isolates Ab1, 
Ab2, Ab3 and Ab15 did not contained a CHDL in addition to the OXA-51-like enzyme, 
suggesting that the OXA-51-like β-lactamase may explain their resistance to carbapenems. It 
is known that the presence of ISAba1 can regulate the expression of OXA-type 
carbapenemases, such as OXA-51-like (Turton et al., 2006a), therefore, PCR experiments 
detecting the presence of ISAba1 upstream the blaOXA-51-like gene were performed in the 









Figure 39. Detection of ISAba1 upstream the blaOXA-51-like gene. L: 100bp DNA ladder. 
As shown in the Figure 39, the isolates Ab1, Ab2 and Ab3 produced an amplicon larger than 
1.5kb, which indicates the presence of an IS element upstream the blaOXA-51-like gene. The 






sequencing of these products confirmed the presence of ISAba1 associated upstream the 
carbapenemase gene. The presence of ISAba1 in the isolates described above should explain 
their increased resistance profiles to carbapenems, in the absence of a transferable CHDL 
(Table 8). It is important to note that the role of the blaOXA-51-like in carbapenem resistance in 
A. baumannii depends on the presence of ISAba1 (Turton et al., 2006a); therefore, two main 
mechanisms of carbapenem-resistance, such as the presence of OXA-58 and association of 
ISAba1 with blaOXA-51-like, have been detected in this thesis, as OXA-23, OXA-24, OXA-143 
and OXA-235 β-lactamases were not detected in the isolates from Chile. 
 
It is interesting to note the versatility of the ISAba1 element as it has been identified 
upstream of the phaBAC gene, which encodes an acetoacetyl-CoA reductase,  and has also 
been detected upstream the blaOXA-23-like gene in A. baumannii (reviewed by Evans et al., 
2013). Additionally, it can be present upstream of the blaADC-like genes, which leads to the 
resistance to cephalosporins (Héritier et al., 2006). Moreover, it has been detected disrupting 
the carO gene, thus preventing its expression and preventing the penetration of the 
antibiotics from the external media (Lee et al., 2011). Furthermore, ISAba1 has been 
identified regulating the expression of sulII (Segal et al., 2005), aac6’Ib (Naas et al., 2007), 
aacC2 (Segal et al., 2003) and blaOXA-58-like (Poirel and Nordmann, 2006); hence, this genetic 
element has an important role in the resistance to different types of antibiotics, such as 
carbapenems, cephalosporins, sulphonamides and aminoglycosides, among others. In the 
specific case of the blaOXA-51-like genes, it has been found that the ISAba1 produces an 
increment of the expression of this gene. In a work published in 2009, it was demonstrated 
that when the ISAba1 element was inserted, in vitro, upstream the blaOXA-51-like gene, the 
MICs values doubled to imipenem (from 2 to 4mg/L) and to meropenem (from 3 to 6mg/L) 
(Figueiredo et al., 2009a). Interestingly, multiple copies of this genetic element are present in 




different mechanisms of antibiotic resistance, giving all Acinetobacter baumannii the 
potential to become MDR when they are under antibiotic pressure. Additionally, the 
presence of multiple copies of this IS element may reflect its mobility and could suggest that 
transposition events occur frequently, producing a variety of arrangement in the genetic 
material of A. baumannii (Segal et al., 2005).  
 
As mentioned earlier in this thesis, the blaOXA-23-like gene has been identified lately in A. 
baumannii collected in Chile between 2011 and 2012, which showed the presence of the 
ISAba1 upstream this OXA-type carbapenemase gene (Opazo Alexis A, Personal 
communication, 2014). This finding reflects the importance of the activity of ISAba1 in the 
regulation of carbapenem-resistance by modulating genes that have been recently identified 
in the country. 
 
The association between ISAba1 and blaOXA-51-like in A. baumannii is not new in South 
America. In a study published in 2012, where 20 isolates from Colombia were analysed, four 
isolates carried the ISAba1 upstream of the blaOXA-51-like gene and additionally six samples 
contained the ISAba1 upstream the blaOXA-23-like (Martínez and Mattar, 2012). In this work, 
the ISAba1 was also mediating the cephalosporin-resistance as it was detected upstream the 
blaADC-7 gene. Interestingly, in a study where carbapenem-resistant isolates from Bolivia 
were analysed, none of them had insertion sequences upstream the blaOXA-51-like gene (Lopes 
et al., 2013). Additionally, isolates from Chile containing the ISAba1 upstream the blaOXA-219 
gene, have been detected (Zander et al., 2012). These findings reflect the major importance 
of ISAba1 in the modulation of the antibiotic resistance not only to carbapenems, but also 





3.4.2.  Genetic environment of blaOXA-58 in the isolates from Chile 
As the blaOXA-58 gene could be present in both plasmids and chromosome (Opazo et al., 
2012b), it is important to analyse in which replicon this gene is located. The plasmids present 
in the Chilean isolates were extracted using a commercial kit described in the Chapter 2 and 
then separated by PFGE. An example gel of the plasmid profiles is shown in the Figure 40. 
As shown in this figure, the strains possessed different plasmids of varying sizes. As the 
isolates Ab1, Ab2, Ab3 and Ab15 did not harbour the blaOXA-58 gene, they were excluded 
from the plasmid extraction experiments.  
 
The isolates harboured large plasmids, most of them larger than 100kb (Figure 40). This fact 
reflects the ability of A. baumannii to capture exogenous DNA, which can provide diverse 
functions, such as antibiotic resistance.  
 
Probably, these plasmids encode not only antibiotic resistance genes, but also could encode 
metabolic genes, metal resistance genes, transposition genes, among others. In order to 
characterise the pool of plasmids present in the isolates, it is necessary to perform further 
analysis, such as the determination of the incompatibility group for each plasmid (Bertini et 



















Figure 40. Example gel of plasmid separated by PFGE. L: Lambda ladder PFG marker. Each 
white arrow indicates a plasmid present in the isolates.  
 
After the plasmid extraction and separation by PFGE, the bands were extracted from the 
agarose gel and the DNA was used as template for PCR experiments (Figure 41A). In order 
to ensure that the DNA extracted corresponded exclusively to plasmid DNA, a PCR to detect 





























Figure 41. Detection of blaOXA-58 in plasmids from Chilean isolates. A: Detection of blaOXA-58 
using the plasmid DNA as template. The letters after the isolate number represent the 
different plasmids detected in each isolate. B: Example gel of the detection of the 
chromosomal 16S gene in the plasmid DNA. C+: Total DNA from Ab1 used as positive 
control. L: 100bp DNA ladder. 
 
 
Of all the Chilean samples analysed, ten isolates harboured the blaOXA-58 gene in plasmids 
(Figure 41). Interestingly, the blaOXA-58 gene was detected in more than one plasmid in each 
sample, indicating that most of them have multiple copies of this gene, as shown in Figure 
41. The exception was isolate Ab13, which had three plasmids (ca.50kb, ca.150kb and 
ca.240 kb) and the blaOXA-58 gene was present only in the largest plasmid (Figure 41).  
A 
B 
     L    4a   5a  5b   5c   6a  6b   6c  C+                L    7a  7b   8a  8b   8c   9a   9b  C+ 
 







Only the samples from Ab4 and Ab10 presented a single plasmid that, in both cases, 
harboured the carbapenemase gene (Figure 41). The isolate Ab14 showed two plasmids 
(ca.48kb and ca.150kb), neither of which contained the blaOXA-58 gene, suggesting that this 
gene was carried in the chromosome (Figure 41). 
 
These results confirm the trend in South America that the location of the blaOXA-58 gene is 
mainly on plasmids. In a study, where 46 isolates collected during 2008 and 2009 in Bolivia 
were analysed, the blaOXA-58 gene was detected in plasmids of ca.40kb (Sevillano et al., 
2012). In another work carried out in Argentina in 2011, the blaOXA-58 was detected on 
plasmids, in which the ISAba825 element was associated upstream the carbapenemase gene 
(Ravasi et al., 2011). These findings suggest that the potential dissemination of this acquired 
CHDL is high, as it is mainly harboured on mobile genetic elements, which could be 
mobilised intra- or inter-species. 
 
The association of blaOXA-58 with insertion sequences was analysed by PCR as described 
earlier in the Materials and Methods chapter. The primers described in the Chapter 2 allow 
the detection of any IS sequence upstream the blaOXA-58 gene; therefore, after the 
amplification of this region by PCR, it was necessary to sequence the products. An example 










Figure 42. Example gel of the detection of ISAba3 upstream the blaOXA-58 gene in isolates 
from Chile. L: 1kb DNA ladder. 
 
Of the eleven samples analysed, the Ab5, Ab6, Ab7, Ab8, Ab9 and Ab16 showed the 
presence of an IS element upstream the blaOXA-58 gene (Figure 42). The PCR products were 
sequenced and compared with the NCBI database (http://www.ncbi.nlm.nih.gov/), revealing 
that all the positive isolates harboured the ISAba3 element both upstream and downstream 
(Figure 43). In addition, the sequences were compared with the data available in ISFinder 
(https://www-is.biotoul.fr/, last accessed February 17th, 2014) as it exclusively contains 




















































Figure 43. Nucleotide sequence of the genetic environment of the blaOXA-58 present in isolate 
Ab5. Red underlined nucleotides: intergenic regions. Blue underlined nucleotides ISAba3-
elements. Not underlined nucleotides: blaOXA-58 gene. 
 
In the six blaOXA-58-positive isolates from Chile, this gene was embedded in a transposon-like 
structure, flanked by two copies of ISAba3 one upstream and the other downstream (Figure 
44). There was a spacer region of 17bp present between the blaOXA-58 gene and the ISAba3-








Figure 44. Genetic structure containing the blaOXA-58 gene in isolates from Chile. The spacer 
region is indicated by the black triangles.  
 
 
The presence of ISAba3 flanking the blaOXA-58 gene was first described in 2003 in an A. 
baumannii isolate from France (Poirel et al., 2005b). This element is commonly associated 
with the blaOXA-58 gene (Evans et al., 2013) and this association has been detected in isolates 
from South America, specifically, in isolates from Bolivia (Lopes et al., 2013) and Argentina 
(Merkier et al., 2008). This genetic element may be playing a role in the regulation of the 
expression of the blaOXA-58 gene, as it is capable of providing a strong promoter, which could 
increase the expression of the gene (Evans et al., 2013). In addition, this IS element may be 
playing an important role in the mobilisation of this carbapenemase gene, as it was found 
bracketing the gene, which could allow its dissemination by homologous recombination 
(Poirel and Nordmann, 2006).  
 
In order to analyse the influence of the ISAba3 in the expression of blaOXA-58, RT-PCR 
experiments were performed as described in Chapter 2. The expression of blaOXA-58 was 
normalised by comparing the intensity band of the gene with the intensity band of the 16S 
gene, which is a constitutive gene (Lopes et al., 2012b). The expression levels were 
compared among all the blaOXA-58 positive samples as shown in the Figure 45. 




















Figure 45. RT-PCR for blaOXA-58 contained in the Chilean isolates. A: RT-PCR for the 
blaOXA-58 gene. B: RT-PCR for the 16S gene. L: 100bp DNA ladder. C-: The isolate Ab15 
was used as negative control for blaOXA-58.  
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The comparison of the intensities of the bands between samples that harboured the ISAba3 
upstream the blaOXA-58 and those where this genetic element was absent resulted in a similar 
expression of the carbapenemase gene (Table 9).  
 
Table 9. Levels of gene expression in Chilean isolates of A. baumannii. * Isolates that 
harboured the ISAba3 upstream the blaOXA-58 gene. 
Strain Expression of blaOXA-
58 



























































The results presented in the Table 9 suggest that the ISAba3 did not produce a significant 
difference with the isolates that do not have this genetic element, as the levels of the 
expression of blaOXA-58 varied between 1.08 and 1.84 (Table 9). These values could be 
explained if the promoter, provided by ISAba3, had a similar activity in comparison with a 
potential promoter present in the samples that do not have this IS element. The limitation of 
this technique in this study is the lack of a chromosomal-positive control, which is used to 
normalise the intensity values. However, in the results presented in the Table 9, it is possible 
to presume about the role of ISAba3 in the expression of blaOXA-58. Further analysis with 
extensive controls and a quantitative RT-PCR are required in order to achieve a complete 
understanding of ISAba3 in the expression of this carbapenemase gene. 
 
It was necessary to analyse the sequence of the upstream region of the isolates that do not 
have the ISAba3 and search for the promoter regions, as probably there are other genetic 
arrangements that are regulating the expression of this gene. In this sense, there have been 
different genetic arrangements involving the presence of ISAba3, such as the insertion of 
ISAba2 into the ISAba3 element in the same orientation of the blaOXA-58 gene, producing an 
hybrid promoter where the -35 region belongs to the ISAba2 element and the -10 region to 
ISAba3 (Poirel and Nordmann, 2006). Furthermore, the IS18 has been detected inserted into 
the ISAba3 element, forming a chimeric promoter that controls the expression of blaOXA-58 
(Poirel and Nordmann, 2006). Another re-arrangement has been represented by the insertion 
of the ISAba825 into the ISAba3, which results in enhanced levels of carbapenem resistance 
(Ravasi et al., 2011). The insertion of IS1008 or ISAba9 into ISAba3 also could produce 
hybrid promoters that result in the increased expression of the blaOXA-58 gene (Chen et al., 





In addition to controlling the expression of carbapenemase genes, the IS elements may have 
an important role in the duplication of these genes. According to a study published in 2007, 
three clonal isolates with MICs of imipenem of 16, 32 and 128mg/l, harboured the blaOXA-58. 
Interestingly, the samples with a MIC of 16mg/l had one copy of blaOXA-58, while the one that 
had a MIC of 32mg/l had two copies and the one with a MIC of 128mg/l contained three 
copies of the carbapenemase gene (Bertini et al., 2007).  
 
By analysing the genetic context of the blaOXA-58 gene, the ISaba2/ISAba3-blaOXA-58-ISAba3 
arrangement was flanked by copies of the IS26 element, which could be involved in 
production of multiple copies of blaOXA-58. This effect of IS elements in achieving the 
duplication of carbapenemases genes is important to investigate as most of the Chilean 
samples harboured more than one copy of blaOXA-58, which could be produced by a similar 
mechanism to that proposed by Bertini et al (2007). 
 
This is the first report of the ISAba3 associated with blaOXA-58 in isolates from Chile, though 
ISAba3 has been found associated with blaOXA-58 elsewhere (reviewed by Evans et al., 2013).  
The lack of national data on the mechanisms of carbapenem resistance in A. baumannii in 
Chile makes it imperative to work on the characterisation of the IS elements that govern the 
mobilisation and expression of the carbapenemases genes. 
 
ISAba3 may be playing a role in the mobilisation of the blaOXA-58 gene in the isolates that 
contained this arrangement (Figure 44), as the carbapenemase gene is contained in a 
transposon-like structure. The presence of the ISAba3 element, associated with the blaOXA-58 
carbapenemase gene, has been detected in isolates from South America, specifically in 




(Lopes et al., 2013). In turn, this genetic arrangement was found in a plasmid of ca. 40kb, 
which provides the possibility to spread this carbapenemase gene among different pathogens.  
 
Interestingly, this genetic arrangement was also identified in a isolate of A. pittii (formerly 
Acinetobacter genomic species 3) with reduced susceptibility to carbapenems, where ISAba3 
was present downstream the blaOXA-58 gene and a truncated copy, which was interrupted by 
ISAba125, was located upstream the carbapenemase gene (Evans et al., 2010). This structure 
may account for the potential dissemination of the blaOXA-58 gene between different species.  
 
3.5.  To characterise the mechanism of ceftazidime-resistance in A. baumannii isolates 
collected in 2008 from Al Ain, UAE. 
 
As described earlier in this thesis, the two isolates (NM55 and NM128) obtained from the 
UAE corresponded to isogenic strains as they exhibited a similarity higher than 90% by 
PFGE (Figure 35) but they showed a marked difference in their MICs values of ceftazidime. 
Furthermore, as described above, the MICs of rifampicin were 2.0mg/l for isolate NM128 
and 32mg/l for isolate NM55. These two MDR-isolates were collected in May (NM55) and 
August (NM128) 2008 from tracheal specimens of a 6-years-old patient in Tawam Hospital, 
Al Ain, UAE. As stated above, the MICs values for ceftazidime were 64mg/l for isolate 
NM55 and 0.2mg/l for the isolate NM128.  
 
In order to characterise the mechanism of ceftazidime-resistance in these samples, a set of 
PCRs were performed as described in the Chapter 2. As the main mechanism of ceftazidime-




blaADC genes, this mechanism was investigated first. The increase of the expression of blaADC 
depends of the presence of genetic elements, such as IS elements, present upstream these 
genes (Ruiz et al., 2007). The sequencing of the blaADC genes revealed that both isolates 
harboured the ADC-26 variant.  
 
The primers utilised in the characterisation of the upstream region of the blaADC genes 
aligned in a conserved gene present further upstream, the GTP cyclohydrolase I gene, thus 
allowing the detection any IS present immediately upstream. If there was no IS present 
upstream of the β-lactamase gene a PCR product of 360bp was obtained. As this was the 










Figure 46. Detection of ISs upstream the blaADC genes. C+: DNA extracted from A. 
baumannii ATCC19606 used as positive control. L: 100bp DNA ladder. 
 
After the characterisation of the upstream region of the blaADC, where both isolates presented 
an identical conformation, the presence of ESBLs was performed by PCR, in order to 
explain the difference of the susceptibility patterns to ceftazidime. As presented in Figure 47, 
the isolate NM55 was positive for ESBLs of the PER family. 










Figure 47. PCR-screening of PER, GES and VEB ESBLs in the isolates from the UAE. L: 
100bp DNA ladder. 
 
 
Through sequencing of the PCR products obtained, the blaPER-like gene was identified as 
blaPER-7 (Figure 48).  
Figure 48. Comparison of the amino acid sequence of the blaPER-like present in the isolate 
NM55 with the sequence available in the NCBI database (http://www.ncbi.nlm.nih.gov/). 
500bp 
 L      NM55   NM128        L       NM55    NM128       L      NM55     NM128 




The PER-like enzymes previously described in A. baumannii were predominantly PER-1 and 
PER-2, which have been identified in isolates from different continents (reviewed by Peleg 
et al., 2008). An isolate collected in 2013 from Kuwait from a 75-years old patient, 
contained the PER-1 enzyme, reflecting the presence of this enzyme group in the Middle 
East. Interestingly, the genetic environment of the gene comprised two copies of the ISPa12 
element, which were flanking the blaPER-1 gene and this genetic structure was also plasmid 
located (Opazo et al., 2014). The activity of the copies of the ISPa12, either side of the 
blaPER-1 gene, could facilitate the spread of this gene. Additionally in this isolate, there was 
an extra mechanism of ceftazidime-resistance, represented by the presence of an ISAba1 
element upstream the blaADC gene, which may account, together with PER-1, for the high 
MIC value of ceftazidime, which was >256mg/l (Opazo et al., 2014).  
 
This work reconfirmed the remarkable capacity of A. baumannii to capture and express 
genes of antibiotic resistance, representing one of the most important factors transforming 
this microbe into a persistent and dangerous nosocomial pathogen. 
 
PER-7 enzyme was first characterised in 2011. This enzyme was present in an isolate 
collected from bronchial aspirate in 2010 from a 30-years old patient hospitalised in Paris, 
France. Compared with PER-1, PER-7 had four aminoacid substitutions, Q119E, V245I, 
R246K and A294T, being more similar to PER-6, which had just one different amino acid 
(Bonnin et al., 2011c). PER-7 possess a higher activity against ceftazidime, compared with 
PER-6, whereas, its activity against carbapenems is lower when compared with PER-6 





Interestingly, both samples, NM55 and NM128, harboured a large plasmid (Figure 49). The 
plasmid extraction and hybridization experiments were performed in the laboratory of 
Professor Tibor Pál, in the UAE. The plasmids sizes were determined by S1 nuclease 
digestion, which showed that the NM55 contained a plasmid of ca. 200kb whereas the 
NM128 harboured a plasmid of ca. 180kb. According to the Southern blotting experiment 
(Figure 49), it was determined that the blaPER-7 gene was located on the large plasmid present 
in the NM55 strain, but not in the plasmid detected in the NM128. Additionally, the plasmid 
from NM55 was not conjugative, irrespective of the recipient utilised. Unlike the previous 
detection of this gene in the French isolate, where it was located in the chromosome (Bonnin 
et al., 2011c), the blaPER-7 from NM55 was located on a plasmid, although without an IS 
















Figure 49. Southern blot of the plasmids extracted from A. baumannii strains NM55 and 
NM128 hybridised with a blaPER-7 probe. The gel on the left shows the plasmid profiles 
obtained by the S1 digestion while the gel on the right shows the hybridisation with the 
specific probe. 1: Ladder 39R861MW; 2: NM55; 3: NM128. 
 
The first report of PER-7 identified the gene was located on the chromosome and associated 
it with a mosaic class 1 integron structure, which belongs to the ISCR1-like family (Bonnin 
et al., 2011c). In order to characterise the genetic platform that contains the PER-7 in the 
NM55, a series of PCRs with different primers were performed as described in the Chapter 
2.  









The amplification and sequencing showed that, as in the case of the French isolate, the 
blaPER-7 was contained in a class 1 integron structure, which also contained the arr-2 and 
cmlA7 genes, conferring resistance to rifampicin and chloramphenicol, respectively (Figure 
50). 
 
Figure 50. Schematic representation of the genetic environment of the blaPER-7 gene in strain 
NM55. Horizontal arrows represent the genetic orientations. Partial genes are represented by 
squares. tnase, transposase. The orf513 gene, which determines the ISCR1-element, is 
highlighted by diagonal lines. 
 
Upstream the blaPER-7 was the 3’-CS region of the class 1 integron that contained the qacEΔ1 
and sul1 genes, but the orf5, which is part of the classic structure of these genetic elements, 
was absent (Figure 50). Immediately downstream of the blaPER-7 gene was a gst gene. 
Interestingly, further downstream there was a portion of an abc transporter and then a 
transposase gene.  
 
The genetic context in which the blaPER-7 from NM55 differed from the chromosomally-
located allele in the French isolate specifically in the downstream region (Figure 51). In the 
case of the French isolate, the ABAYE3396 gene was located downstream, while in the case 





Figure 51. Schematic map representing the genetic environment surrounding the blaPER-7 in 
the AP2 strain from France (Bonnin et al., 2011c). 
 
This ISCR1 structure has been identified in different species. Specifically, it was described in 
Aeromonas punctata isolated in China (Xia et al., 2010). In this case, the blaPER-1 was located 
in this genetic platform. This could indicate that probably this genetic structure originated in 
a different bacterial species. 
 
As described above, the downstream region in the NM55 strain was flanked by an abc 
transporter gene, which was interrupted by a transposase gene. This indicates a probable 
insertion of the ISCR1 element in this specific locus, which may suggest a hot spot for the 
integration of mobile genetic elements. In addition, the variable zone of the mosaic class 1 
integron in the UAE strain NM55 contained the arr-2 gene, which explains the reduced 
susceptibility to rifampicin, in comparison with the NM128 strain (Figure 50). Moreover, the 
NM55 strain contained the cmlA7 gene, which confers resistance to chloramphenicol; 
however, both strains were resistant to this antibiotic, suggesting that the mechanism of 
resistance was not due only by the presence of this gene.  
 
Despite the previously described differences, there are some similarities between the French 




which is one of the most common genes of this family present in the Middle East (Opazo et 
al., 2012a). It is notable that the French isolate was collected in 2010 while the NM55 strain 
was isolated about two years earlier. This chronology may suggest that the blaPER-7 was 
originally carried into strains of A. baumannii on plasmids, and probably some of the 
integrons were mobilised to the chromosome. In the results presented in this thesis, the 
plasmid was not conjugative, thus the mechanism of its uptake is still to be analysed.  
 
These results showed once more the remarkably ability of A. baumannii to capture and/or 
lose genes, during which process elements, such as ISCR1, could be involved. Interestingly, 
in the case of the strains from the UAE, the blaPER-7 was lost after four months, leaving the 
resulting strain, NM128, susceptible to ceftazidime. The reasons of this loss are not easy to 
explain in an environment where cephalosporins are being used frequently.  
 
Finally, the NM55 and NM128 strains derived from the same patient, showing PFGE 
patterns of more than 90% similarity, which suggests that the smaller plasmid (NM128) 
derived from the plasmid contained in the NM55 strain, which had a suffered a deletion, 





Chapter 4 Conclusions 
 
The results obtained in this thesis showed that the Mobilome is playing an important role in 
the ceftazidime- and carbapenem-resistance in MDR-A. baumannii from Chile and the UAE. 
  
In the case of the Chilean isolates, the Mobilome was composed by plasmids harbouring the 
blaOXA-58 enzyme in 12 of the 15 samples analysed. In turn, another member of the 
Mobilome, the ISAba3-element, was associated with blaOXA-58, forming a transposon-like 
structure. Even though the results need to be validated, they show that ISAba3 would not be 
involved in the expression of blaOXA-58. In addition, another IS element, ISAba1 was present 
in the Chilean carbapenem-resistant strains that do not harbour the acquired blaOXA-58. This 
element was located upstream the blaOXA-51-like genes, which may be causing the over-
expression of these carbapenemases genes. On the other hand, it is necessary to characterised 
the isolates by MLST in order to determine whether they are part of the 3 widely spread ICs 
or whether they belong to different local lineages. 
 
In the case of the Emirati isolates, the resistance to ceftazidime was mediating by the 
Mobilome, which consisted of plasmids harbouring the ISCR1-element, which, in turn, 
contained the uncommon blaPER-7 ESBLs gene. The structure of this genetic platform 
represents a new genetic context harbouring this gene, which reflects the remarkable ability 
of A. baumannii to capture and express genes making it a pathogen with a high ability to 
survive under adverse conditions. Additionally, the ISCR1-element harboured two extra 
resistance genes, such as arr-2 and clmA7, conferring resistance to more than a specific 




To conclude, the role of the Mobilome in the strains analysed is to spread and to regulate the 
expression of resistance genes in A. baumannii by the presence of several members of this 
group, such as ISs, transposons-like structures, plasmids and the ISCR1-elements. The 
results of this thesis suggest that MDR-A. baumannii isolates can act as reservoir of 
resistance genes, where elements belonging to the Mobilome could mediate the mobilisation 
from resistance to susceptible cells, which might produce a widely appearance of MDR 
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Acinetobacter baumannii has emerged as one of the most important microorganism causing 
infections in hospitalized patient. The only remaining options for the treatment of serious 
infectious diseases causes by multi-resistant A. baumannii are carbapenems, such as imipenem 
and meropenem; cephalosporins and colistin. Resistance to oxyiminocephalosporins 
(ceftazidime and cefotaxime) has been associated with the insertion sequence ISAba1 
providing a strong promoter to ADC-genes. 
 
3 strains of A. baumannii isolated in Al Ain, UAE, designated Nm55, Nm57 and Nm128, were 
studied. Nm57 was isolated from an intravenous catheter tip of an adult patient, Nm55 and 
Nm128 were both isolated from sputum samples taken 7 days apart from a 6 year old patient. 
They were confirmed as A. baumannii by PCR detecting the blaOXA-51-like gene and sequencing 
the rpoB gene. Genotypic characterization was performed by macro-restriction assay followed 
by pulsed-field gel electrophoresis (PFGE), using the ApaI enzyme. Antibiotic susceptibility 
was performed by disk diffusion test according to BSAC guidelines. Determination of minimal 
inhibitory concentration (MIC) of ceftazidime was performed by the agar dilution method 
according to BSAC recommendations. Detection of blaOXA genes was performed by multiplex-
PCR and detection of ISAba1 and ADC was done by standard-PCR using specific primers.  
 
All the strains were designated as identical as they showed more than 94% similarity according 
to PFGE pattern and were all MLST type ST110. All three strains were resistant to imipenem, 
meropenem, cefotetan, aztreonam, cefoperazone, cefepime, cefotaxime and cefpodoxime. 
Strain Nm55 was resistant to ceftazidime, while Nm57 was intermediate and Nm128 was 
susceptible. All the strains harbour both OXA-64 chromosomal and the OXA- -
lactamases. ISAba1 was upstream of the blaOXA-23 genes in all three strains and was responsible 
for carbapenem resistance. All the strains harboured the same blaADC gene but in no case was 





This study shows a rare example of an A. baumannii strain that was resistant to carbapenems 
but was sensitive to ceftazidime. When the strain progressed to ceftazidime resistance this was 
not by the reported method of an insertion of an ISAba1-like element upstream blaADC gene 
providing the necessary promoter. 
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Objective 
Analyse the role of IS26 in the non-susceptible carbapenem phenotype of Ab-Ch5 strain 
isolated in Chile. 
 
Methods 
Species-identification was carried out by amplification of blaOXA-51-like gene and by sequencing 
of a 455bp section of the rpoB gene. Determination of the minimal inhibitory concentration 
(MIC) of carbapenems was performed by the agar double diffusion method. Detection of 
carbapenemase genes, insertion elements and the characterisation of the genetic environment 
of blaOXA-58 were carried out by PCR. Plasmids were analysed by the use of commercial kits. 
Expression of blaOXA-58 was determined by RT-PCR. 
 
Results 
MICs values of imipenem and meropenem were 8.0 mg/L and 4.0 mg/L, respectively. Strain 
Ab-Ch5 harboured both blaADC-like and blaOXA-58. The blaOXA-51-like variant was the blaOXA-51 
gene itself without the presence of ISAba1 element upstream. The characterisation of the 
genetic environment of blaOXA-58 showed the presence of IS26-∆ISAba3 arrangement upstream 
and an intact ISAba3-element downstream. The blaOXA-58 was detected in a plasmid of ca. 260 
kb. There were not differences in the expression of blaOXA-58 in comparison with an ISAba3-
blaOXA-58 carbapenem-resistant strain. 
 
Conclusion 
The interruption of ISAba3 by the IS26-element upstream does not affect the control of the 
expression of the OXA-58 β-lactamase in strain Ab-Ch5. The presence of blaOXA-58 in a 
plasmid represents a source of horizontal dissemination of this carbapenemase gene in which 
IS26 may play an important role. This is the first report detecting the association of IS26 with 
blaOXA-58 in a strain isolated in South America. 
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